Absorbent article and method for maintaining or improving skin health

ABSTRACT

Disclosed is a method for maintaining and/or improving skin health in the area of a wearer covered by an absorbent article. The absorbent article includes a vapor permeable backsheet, a liquid pervious topsheet positioned in facing relation with the backsheet, an absorbent core located between the backsheet and the topsheet. The absorbent article also includes skin care compositions thereon for maintaining and/or improving skin health.

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. application Ser. No.12/946,926, filed on Nov. 16, 2010 now U.S. Pat. No. 8,138,388, which isa continuation of U.S. application Ser. No. 11/472,019, filed on Jun.21, 2006, now U.S. Pat. No. 7,851,668, which is a continuation of U.S.application Ser. No. 10/027,295, filed on Dec. 20, 2001 now abandoned,which is a divisional of U.S. application Ser. No. 08/926,532, filed onSep. 10, 1997, now U.S. Pat. No. 6,803,496, which is acontinuation-in-part of U.S. application Ser. No. 08/884,069, filed onJun. 27, 1997, now U.S. Pat. No. 6,118,041, which is a continuation ofU.S. application Ser. No. 08/345,159, filed Nov. 28, 1994, now U.S. Pat.No. 5,643,588, each of which is hereby incorporated by reference in itsentirety.

TECHNICAL FIELD

This application relates to a method for maintaining or improving skinhealth in wearers of absorbent articles such as diapers, training pants,adult incontinence devices, feminine hygiene products, and the like.More particularly, the application relates to a method comprising therepeated use of absorbent articles that deliver a composition to thewearer's skin, so as to provide a skin protective barrier and/or atherapeutic benefit.

BACKGROUND OF THE INVENTION

Many types of disposable absorbent products, such as diapers, areavailable that have a high capacity for absorbing urine and other bodyexudates. Disposable products of this type generally comprise some sortof liquid-pervious topsheet material, an absorbent core, and aliquid-impervious backsheet material. Although these types of absorbentstructures may be highly efficient for the absorption of liquids, it iswell recognized that long-term wear of such structures may lead to skinwhich is compromised in terms of being over hydrated or exposed to skinirritants commonly found in body exudates. It is generally known thatskin under absorbent articles is more susceptible to skin disorders,including diaper rash, erythema (i.e., redness), heat rash, abrasion,pressure marks and skin barrier loss. For example, 21 C.F.R. 333.503defines diaper rash as “[a]n inflammatory skin condition in the diaperarea (perineum, buttocks, lower abdomen, and inner thighs) caused by oneor more of the following factors: moisture, occlusion, chafing,continued contact with urine or feces or both, or mechanical or chemicalirritation.”

To address the concerns of skin disorders associated with wearingabsorbent articles, the caregiver often applies skin protective productssuch as Vaseline®, medicated ointments, powders, etc. to the buttocks,genitals, anal and/or other regions before placing the absorbent articleon the wearer. This procedure usually involves the caregiver applyingthe skin protective to their hands, and then wiping the same on the skinof the infant. To eliminate the need for this wasteful, messy,time-consuming, and easily forgotten procedure, there have been attemptsto prepare absorbent articles which contain a protective or therapeuticskin care substance on the article's topsheet.

U.S. Pat. No. 3,585,998 to Hayford et al. teaches a disposable babydiaper, an interior liner of which carries an array ofpressure-rupturable capsules containing baby oil. The patent teachesthat it is desirable to break the capsules prior to using the diaper byapplying pressure with such household items as a rolling pin, hand iron,etc. Articles disclosed by this patent have serious drawbacks. Namely,unless the capsules are ruptured by applying pressure prior to using thediaper or the bandage, the skin-care substance contained in the capsulesis either not delivered at all or is delivered non-uniformly leavingsome areas of skin uncoated.

U.S. Pat. No. 3,489,148 to Duncan et al. teaches a baby diapercomprising a hydrophobic and oleophobic topsheet wherein a portion ofthe topsheet is coated with a discontinuous film of oleaginous material.A major disadvantage of the diapers disclosed in the Duncan et al.reference is that the hydrophobic and oleophobic topsheets are slow inpromoting transfer of urine to the underlying absorbent cores.

U.S. Pat. No. 5,643,588 to Roe et al. addresses some of the concernspresented by prior absorbent articles which were designed to deliver askin protective material. In particular, Roe describes an absorbentarticle whose topsheet is surface treated with a lotion that comprisesan emollient for facilitating easier cleaning of feces and otherexudates and an agent which immobilizes the lotion so that it does notmigrate from the point of initial application.

While the prior art describes articles designed to deliver compositionsto provide skin care benefits, the prior art has failed to describe aregimen which results in maintained or improved skin health in regionsof the wearer's body covered by absorbent articles, where the regimendoes not require intervention from the caregiver in the form of manualapplication of skin care compositions. That is, the prior art has notrecognized the importance of the repeated use of absorbent articles thatautomatically deliver sufficient levels of a composition to the wearer'sskin that allows the maintenance or improvement of skin health in theregion of the wearer covered by the absorbent article.

Accordingly, it would be desirable to provide a method: (1) wherein thecondition of skin covered by the absorbent article is maintained in anatural, healthy condition or improved to a more healthy condition; and(2) that does not require intervention by the wearer or caregiver in theform of manual application of skin care agents.

Therefore, it is an object of the present invention to provide a methodfor maintaining or improving the skin health of an absorbent articlewearer comprising repeated application of disposable absorbent articlesthat automatically deliver sufficient levels of a composition. In thisregard, it is an object of the present invention to provide a methodthat comprises the application of absorbent articles which have acomposition on a wearer-contacting surface, where the composition istransferable to the wearer's skin and is effective at maintaining orimproving skin health.

These and other objects are obtained in accordance with the presentinvention, as will become readily apparent upon reading the followingdisclosure.

SUMMARY OF THE INVENTION

The present invention relates to a method for maintaining and/orimproving skin health in the area of a wearer covered by an absorbentarticle. The absorbent article includes a vapor permeable backsheet, aliquid pervious topsheet positioned in facing relation with thebacksheet, an absorbent core located between the backsheet and thetopsheet. The absorbent article also includes skin care compositionsthereon for maintaining and/or improving skin health. The methodcomprising the following steps:

-   -   (a) applying to the wearer an absorbent article having a skin        care composition that provides a therapeutic and/or protective        skin benefit upon transfer to the skin;    -   (b) transferring to the wearer at least a portion of the skin        care composition during wear; and    -   (c) repeating steps (a) and (b) with one or more additional        articles with sufficient frequency to maintain or improve the        health of the skin covered by the absorbent article relative to        the skin covered by an equivalent absorbent article that does        not comprise the skin care composition, and without the need for        manual application of skin protective agents (e.g., by the        caregiver or wearer).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an absorbent article in the form of a diaper according to thepresent invention.

FIG. 2 a through 2 e depict the regions of a wearer of absorbent articlethat are assessed for rash and erythema.

FIG. 3 a is a side view showing placement of the skin analog used in theskin care composition transfer test.

FIG. 3 b is a plan view showing placement of the skin analog used in theskin care composition transfer test.

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

As used herein, the term “comprising” means that the various components,ingredients, or steps, can be conjointly employed in practicing thepresent invention. Accordingly, the term “comprising” encompasses themore restrictive terms “consisting essentially of” and “consisting of”

As used herein, the term “maintained” skin health means to preserve thenatural state of healthy skin. The term “improved” skin health refers toa reduction in the extent of adverse skin effects. These terms describeskin health in the area covered by absorbent articles. It will berecognized that the methods of the present invention may both maintainand improve skin health in different regions of an individual wearer.

As used herein, the term “skin care composition” refers to anycomposition which comprises one or more agents which, when transferredfrom an article to a wearer's skin, provide a therapeutic and/orprotective skin benefit. Representative materials are discussed indetail below.

As used herein, the term “treated article” means an absorbent articlehaving a skin care composition on or migratable to at least onewearer-contacting surface of that article. An “equivalent article thatdoes not comprise a skin care composition” is an article that issubstantially the same as a treated article, in terms of topsheet,backsheet, absorbent core, chassis design, cuffs, etc., but which doesnot comprise a skin care composition that is transferred to the wearerduring use.

As used herein, the term “wearer-contacting surface” of an absorbentarticle is one or more surfaces of any article components that contactthe wearer at some time during the wear period. Wearer contactingsurfaces include, but are not limited to, portions of the topsheet, legcuffs, waist region, side panels, fastening tabs, etc., which contact awearer during use.

Other terms are defined in the specification where initially discussed.

With respect to the skin care composition, all percentages, ratios andproportions used herein are by weight unless otherwise specified.

II. Methods for Maintaining and/or Improving Skin Health

As discussed, the adverse skin effects that result from the occlusivenature of current absorbent articles are well recognized. Efforts havebeen made to overcome these negative attributes by preparing articlesthat deliver beneficial compositions. However, Applicants are the firstto recognize the benefit of a method comprising frequent cycles ofcumulative delivery of a skin care composition to the wearer's skin tomaintain or improve skin health. In this regard, the present inventionrelates to a method for maintaining or improving skin health in the areacovered by an absorbent article, the method comprising the followingsteps:

-   -   (a) applying to the wearer an absorbent article having a skin        care composition that provides a therapeutic and/or protective        skin benefit upon transfer to the skin;    -   (b) transferring to the wearer at least a portion of the skin        care composition during wear; and    -   (c) repeating steps (a) and (b) with one or more additional        articles with sufficient frequency to maintain or improve the        health of the skin covered by the absorbent article relative to        the skin covered by an equivalent absorbent article that does        not comprise the skin care composition, and without the need for        manual application of skin protective agents (e.g., by the        caregiver or wearer).

Applicants have discovered that, surprisingly, maintaining or improvinghealth skin under absorbent articles can be accomplished coincidentally(or “automatically”) with repeated use, over a period of time (e.g.,several days), of absorbent articles that are treated with a compositionthat is transferred to the wearer under normal usage conditions (e.g.,contact, movement, handling by the caregiver after application of thearticle, body heat, etc.). Thus, while prior attempts to address skindisorders associated with wearing absorbent articles have generallydescribed steps (a) or (b) of the present method, none of those attemptsappreciated the importance of step (c), corresponding to frequent cyclesof cumulative delivery of a skin care composition to the wearer's skinto maintain or improve skin health. Applicants have further discoveredthat delivery of relatively low levels of the composition with eacharticle wear are sufficient to obtain the skin benefits resulting fromthis novel method of cumulative composition delivery.

The article used in the present methods provides an available sourcefrom which the skin care composition transfers onto the skincontinuously over time. As the composition is transferred, itaccumulates on the skin surface to initiate and maintain its protectiveactivity. As a used article is discarded and replaced by a new one, thiscycle is repeated for further composition accumulation above and beyondwhat a single or original article would have delivered on its own.Certain of the ingredients for use in the composition are known topenetrate the stratum corneum (e.g., petrolatum, which is preferred foruse herein). Thus, even as some amount of the composition is removed bycleaning, bathing, etc., or even if usage of treated articles asdescribed herein is discontinued temporarily, some of the benefits ofthe skin composition will remain with the user. As usage of treatedarticles is resumed before all of the benefits of the composition havedissipated, the user will derive benefits, in terms of reduced erythemaand/or rash, more rapidly than would a user who has not used treatedarticles.

As indicated above, it is generally recognized that skin under absorbentarticles is more susceptible to degradation of that skin's condition.Typically, cutaneous manifestations of these skin conditions includeredness (also referred to as erythema) and/or rash. As such, Applicantsdescribe herein a method for maintaining or improving skin health inregions covered by an absorbent article, wherein the desired endpoint ofthe method is the reduction or avoidance of erythema and/or rash whencompared to skin covered by an equivalent absorbent article that doesnot comprise the skin care composition.

Erythema and rash are the most common and well documented adversemedical conditions present on skin covered by absorbent articles. Theseconditions are readily assessed by expert skin graders. Hence theprotocol for assessing the maintenance or improvement of skin healthrelies on assessment of rash and/or erythema. The protocol for assessingreduction or avoidance of rash and/or erythema provided by the methodsof the present invention are described in detail in the Test Methodssection below. In brief, the objective of the protocol is to determinewhether use of a test article reduces the frequency and/or severity ofskin rash and/or erythema in the diapered skin regions compared to anequivalent, untreated article. The test method involves comparisons ofend point parameters between 2 groups of subjects who are assigned towear the test or the control product for 3 consecutive weeks (a baselineweek in which all subjects use the same control product is includedprior to initiating the 3-week product comparison portion of the study).Per this approach, the skin in the diapered region of the users of thearticles is examined twice per week at 3-4 day intervals by a clinicalevaluator trained to evaluate diaper rash and erythema using a definedscale. At the completion of the study, the frequency and severity ofdiaper rash and erythema are compared between the test and controlproduct groups using appropriate statistical procedures.

In one aspect, the improvement manifests itself as a statisticallysignificant reduction in erythema and/or rash at a 90% confidence level,relative to skin covered an equivalent absorbent article that does notcomprise the skin care composition. In this regard, it is preferablethat the reduction or will manifest itself at a 95% confidence level.

Separately, it is recognized that one may observe large between-groupdifferences (i.e., in the mean) in rash and/or erythema scores, yet dueto large inter-subject variability fail to observe traditionalstatistically significant differences. In this regard, improvements ofat least about 10% between group (control and test) means, though notnecessarily statistical, may be recognized and appreciated by caregiversand users as providing skin care benefits. In this regard, the methodsof the present invention will result in improvements in rash or erythemascores of at least about 10%, more preferably at least about 15%, stillmore preferably at least about 20%.

For purposes of the present disclosure, statistical or non-statisticalimprovements, defined above, in skin condition with regard to eithererythema or rash at one or more wearer regions for the study group as awhole, or any gender or age or size subset of the study group, asdescribed in the Test Method section, are considered to provide thedesired skin benefits of the present invention. Preferably, the methodsof the present invention will provide both erythema and rash benefits,at one or more wearer regions as described in the Test Method section.

III. Skin Care Composition

While the specific composition(s) delivered (referred to herein as “skincare composition” and “composition”) in accordance with the presentmethod is not the critical factor in achieving maintained skin conditionof the area under absorbent articles, it is apparent that thecomposition must provide either a protective, nonocclusive function(e.g., a relatively liquid impervious but vapor pervious barrier) toavoid skin hyperhydration and skin exposure to materials contained inbody exudates, or it must contain agents that deliver, either directlyor indirectly, skin care benefits. For example, indirect benefitsinclude improved removal of skin irritants such as feces or urine. Thecomposition may be in a variety of forms, including, but not limited to,emulsions, lotions, creams, ointments, salves, powders, suspensions,encapsulations, gels, and the like.

As used herein, the term “effective amount of a skin care composition”refers to an amount of a particular composition which, when applied ormigrated to one or more of the wearer-contacting surface(s) of anabsorbent article(s), will be effective in providing a protectivebarrier and/or delivering a skin care benefit when delivered viaabsorbent articles over time. Of course, the effective amount ofcomposition applied to the article will depend, to a large extent, onthe particular composition used. Nonetheless, the quantity of thecomposition on at least a portion of the wearer-contacting surface ofthe absorbent article will preferably range from about 0.05 mg/m²(0.0078 mg/cm²) to about 80 mg/m² (12 mg/cm²), more preferably fromabout 1 mg/m² (0.16 mg/cm²) to about 40 mg/m² (6 mg/cm²), still morepreferably from about 4 mg/m² (0.6 mg/cm²) to about 26 mg/m² (4 mg/cm²).These ranges are by way of illustration only and the skilled artisanwill recognize that the nature of the composition will dictate the levelthat must be applied to achieve the desired skin benefits, and that suchlevels are ascertainable by routine experimentation in light of thepresent disclosure.

While the level of skin care composition applied to the absorbentarticle is an important aspect of the present methods, more important isthe amount of composition transferred to the wearer's skin during use ofone or more treated articles. Though the requisite level delivered tothe skin to provide the desired skin benefits will depend to some degreeon the nature of the composition employed, Applicants have found thatrelatively low levels may be delivered while still providing the desiredskin effects. This is particularly true for preferred compositions, suchas that described in Example 1.

Another benefit of the present method is the controlled application ofthe skin care composition to deliver the low but effective levels ofcomposition required. This is in contrast to typically sporadic manualapplication of skin care agents, where the caregiver/user often appliessignificantly greater levels of material than are needed. Excessivematerials added manually may adversely impact the fluid handlingproperties of the absorbent article, as a result of transfer from theskin to the article. Indeed, for certain materials, such as petrolatum,the levels applied manually may actually result in an occlusive effect,thereby compromising the skin. A benefit of the present methods isproviding a barrier to surface moisture while avoiding occlusion of theskin (i.e., maintaining skin breathability). Thus, the present methods,which allow controlled composition delivery throughout the wear period,allow transfer of optimal levels of the composition to the skin tomaintain and/or improve skin health.

The method for determining the amount of skin care compositiontransferred to a wearer's skin after wearing one or more treatedarticles is described in the Test Methods section below. With regard tothe level of skin care composition that is transferred to the wearerduring use of one treated absorbent article worn for a period of about 3hours (a typical daytime wear time), particularly for preferred skincare compositions such as that described in Example 1, preferred iswhere at least about 0.01 mg/m² (0.0016 mg/cm²), more preferably atleast about 0.05 mg/m² (0.0078 mg/cm²), still more preferably at leastabout 0.1 mg/m² (0.016 mg/cm²), of the composition is transferred to theskin over a three hour wear period. Typically, the amount of compositiondelivered by one treated article will be from about 0.01 mg/m² (0.0016mg/cm²) to about 5 mg/m² (0.78 mg/cm²), more preferably from about 0.05mg/m² (0.0078 mg/cm²) to about 3 mg/m² (0.47 mg/cm²), still morepreferably from about 0.1 mg/m² (0.016 mg/cm²) to about 2 mg/m² (0.31mg/cm²), over a three hour wear period.

For continual use of treated articles (in other words, changes occur inaccordance with normal use patterns, which typically include changesevery 3 to 4 hours during the day and a fresh article before overnightsleep) such as for a period of 24 hours, it will be preferred that atleast about 0.03 mg/m² (0.0047 mg/cm²), more preferably at least about0.1 mg/m² (0.016 mg/cm²), still more preferably at least about 0.3 mg/m²(0.047 mg/cm²), of the composition is transferred to the wearer's skinover the 24 hour period. Typically, the amount of composition deliveredafter a period of 24 hours where treated articles are applied at eachchange, will be from about 0.03 mg/m² (0.0047 mg/cm²) to about 18 mg/m²(2.79 mg/cm²), more typically from about 0.1 mg/m² (0.016 mg/cm²) toabout 10 mg/m² (1.55 mg/cm²), still more typically from about 0.3 mg/m²(0.047 mg/cm²) to about 6 mg/m² (0.93 mg/cm²).

It will be recognized that of the numerous materials useful in the skincare compositions delivered to skin in accordance with the presentmethods, those that have been deemed safe and effective skin care agentsare logical materials for use herein. Such materials include Category Iactives as defined by the U.S. Federal Food and Drug Administration's(FDA) Tentative Final Monograph on Skin Protectant Drug Products forOver-the-Counter Human Use (21 C.F.R. §347), which presently include:alantoin, aluminum hydroxide gel, calamine, cocoa butter, dimethicone,cod liver oil (in combination), glycerine, kaolin, petrolatum, lanolin,mineral oil, shark liver oil, white petrolatum, talc, topical starch,zinc acetate, zinc carbonate, zinc oxide, and the like. Otherpotentially useful materials are Category III actives as defined by theU.S. Federal Food and Drug Administration's Tentative Final Monograph onSkin Protectant Drug Products for Over-the-Counter Human Use (21 C.F.R.§347), which presently include: live yeast cell derivatives, aldioxa,aluminum acetate, microporous cellulose, cholecalciferol, colloidaloatmeal, cysteine hydrochloride, dexpanthanol, Peruvean balsam oil,protein hydrolysates, racemic methionine, sodium bicarbonate, Vitamin A,and the like.

Many of the FDA monographed skin care ingredients are currently utilizedin commercially available skin care products, such as A and D® Ointment,Vaseline® Petroleum Jelly, Desitin® Diaper Rash Ointment and Daily Care®ointment, Gold Bond® Medicated Baby Powder, Aquaphor ® Healing Ointment,Baby Magic® Baby Lotion, Johnson's Ultra Sensitive® Baby Cream. Thesecommercial products may be applied to absorbent articles to createtreated articles for use in the present methods, either with or withoutmodification of the product to facilitate delivery via this novelmethod.

As will be discussed hereinafter, the skin care compositions useful inthe methods of the present invention preferably, though not necessarily,have a melting profile such that they are relatively immobile andlocalized on the wearer-contacting surface of the article at roomtemperature, are readily transferable to the wearer at body temperature,and yet are not completely liquid under extreme storage conditions.Preferably, the compositions are easily transferable to the skin by wayof normal contact, wearer motion, and/or body heat. Because thecomposition preferably is substantially immobilized on the article'swearer-contacting surface, relatively low levels of composition areneeded to impart the desired skin care benefits. In addition, specialbarrier or wrapping materials may be unnecessary in packaging thetreated articles useful in the methods of the present invention.

In a preferred embodiment, the skin care compositions useful herein aresolid, or more often semi-solid, at 20° C., i.e. at ambienttemperatures. By “semisolid” is meant that the composition has arheology typical of pseudoplastic or plastic liquids. When no shear isapplied, the compositions can have the appearance of a semi-solid butcan be made to flow as the shear rate is increased. This is due to thefact that, while the composition contains primarily solid components, italso includes some minor liquid components. Preferably, the compositionsof the present invention have a zero shear viscosity between about1.0×10⁶ centipoise and about 1.0×10⁸. More preferably, the zero shearviscosity is between about 5.0×10⁶ centipoise and about 5.0×10⁷centipoise. As used herein the term “zero shear viscosity” refers to aviscosity measured at very low shear rates (e.g., 1.0 sec⁻¹) using plateand cone viscometer (a suitable instrument is available fom TAInstruments of New Castle, Del. as model number CSL 100). One of skillin the art will recognize means other than high melting point components(as discussed below) can be used to provide comparable viscositiesmeasured for such compositions comprising such means can be measured byextrapolating a plot of viscosity vs. shear rate for such compositionsto a shear rate of zero at a temperature of about 20° C.

Preferred compositions are at least semi-solid at room temperature tominimize composition migration. In addition, the compositions preferablyhave a final melting point (100% liquid) above potential “stressful”storage conditions that can be greater than 45° C. (e.g., warehouse inArizona, car trunk in Florida, etc.). Representative compositions havingthese melt characteristics are described in detail in U.S. Pat. No.5,643,588 (Roe et al.), U.S. Pat. No. 5,607,760 (Roe et al.), U.S. Pat.Nos. 5,609,587, and 5,635,191, the disclosure of each of which isincorporated herein by reference. Specifically, preferred compositionswill have the following melt profile:

Characteristic Preferred Range Most Preferred % liquid at  2-50  3-25room temp. (20° C.) % liquid at 25-95 30-90 body temp. (37° C.) finalmelting point (° C.) ≧38 ≧45

By being solid or semisolid at ambient temperatures, preferredcompositions do not have a tendency to flow and migrate to a significantdegree to undesired locations of the article to which they are applied.This means less skin care composition is required for impartingdesirable therapeutic, protective and/or conditioning benefits.

To enhance immobility of preferred compositions, the viscosity of theformulated compositions should be as high as possible to prevent flowwithin the article to undesired location. Unfortunately, in someinstances, higher viscosities may inhibit transfer of composition to thewearer's skin. Therefore, a balance should be achieved so theviscosities are high enough to keep the compositions localized on thesurface of the article, but not so high as to impede transfer to thewearer's skin. Suitable viscosities for the compositions will typicallyrange from about 5 to about 500 centipoise, preferably from about 5 toabout 300 centipoise, more preferably from about 5 to about 100centipoise, measured at 60° C. using a rotational viscometer (a suitableviscometer is available from Lab Line Instruments, Inc. of Melrose Park,Ill. as Model 4537). The viscometer is operated at 60 rpm using a number2 spindle.

For compositions designed to provide a therapeutic and/or skinprotective benefit, a useful active ingredient in these compositions isone or more skin protectants or emollients. As used herein, the term“emollient” is a material that protects against wetness or irritation,softens, soothes, supples, coats, lubricates, moisturizes, protectsand/or cleanses the skin. (It will be recognized that several of themonographed actives listed above are “emollients”, as that term is usedherein.) In a preferred embodiment, these emollients will have either aplastic or liquid consistency at ambient temperatures, i.e., 20° C.Representative emollients useful in the present invention include, butare not limited to, emollients that are petroleum-based; sucrose esterfatty acids; polyethylene glycol and derivatives thereof; humectants;fatty acid ester type; alkyl ethoxylate type; fatty acid esterethoxylates; fatty alcohol type; polysiloxane type; propylene glycol andderivatives thereof; glycerine and derivatives thereof, includingglyceride, acetoglycerides, and ethoxylated glycerides of C₁₂-C₂₈ fattyacids; triethylene glycol and derivatives thereof; spermaceti or otherwaxes; fatty acids; fatty alcohol ethers, particularly those having from12 to 28 carbon atoms in their fatty chain, such as stearic acid;propoxylated fatty alcohols; other fatty esters of polyhydroxy alcohols;lanolin and its derivatives; kaolin and its derivatives; any of themonographed skin care agents listed above; or mixtures of theseemollients. Suitable petroleum-based emollients include thosehydrocarbons, or mixtures of hydrocarbons, having chain lengths of from16 to 32 carbon atoms. Petroleum based hydrocarbons having these chainlengths include mineral oil (also known as “liquid petrolatum”) andpetrolatum (also known as “mineral wax,” “petroleum jelly” and “mineraljelly”). Mineral oil usually refers to less viscous mixtures ofhydrocarbons having from 16 to 20 carbon atoms. Petrolatum usuallyrefers to more viscous mixtures of hydrocarbons having from 16 to 32carbon atoms. Petrolatum and mineral oil are particularly preferredemollients for compositions of the present invention.

Suitable fatty acid ester type emollients include those derived fromC₁₂-C₂₈ fatty acids, preferably C₁₆-C₂₂ saturated fatty acids, and shortchain (C₁-C₈, preferably C₁-C₃) monohydric alcohols. Representativeexamples of such esters include methyl palmitate, methyl stearate,isopropyl laurate, isopropyl myristate, isopropyl palmitate, ethylhexylpalmitate and mixtures thereof. Suitable fatty acid ester emollients canalso be derived from esters of longer chain fatty alcohols (C₁₂-C₂₈,preferably C₁₂-C₁₆) and shorter chain fatty acids e.g., lactic acid,such as lauryl lactate and cetyl lactate.

Suitable alkyl ethoxylate type emollients include C₁₂-C₂₂ fatty alcoholethoxylates having an average degree of ethoxylation of from about 2 toabout 30. Preferably, the fatty alcohol ethoxylate emollient is selectedfrom the group consisting of lauryl, cetyl, and stearyl ethoxylates, andmixtures thereof, having an average degree of ethoxylation ranging fromabout 2 to about 23. Representative examples of such alkyl ethoxylatesinclude laureth-3 (a lauryl ethoxylate having an average degree ofethoxylation of 3), laureth-23 (a lauryl ethoxylate having an averagedegree of ethoxylation of 23), ceteth-10 (a cetyl alcohol ethoxylatehaving an average degree of ethoxylation of 10) and steareth-10 (astearyl alcohol ethoxylate having an average degree of ethoxylation of10). When employed, these alkyl ethoxylate emollients are typically usedin combination with the petroleum-based emollients, such as petrolatum,at a weight ratio of alkyl ethoxylate emollient to petroleum-basedemollient of from about 1:1 to about 1:5, preferably from about 1:2 toabout 1:4.

Suitable fatty alcohol type emollients include C₁₂-C₂₂ fatty alcohols,preferably C₁₆-C₁₈ fatty alcohols. Representative examples include cetylalcohol and stearyl alcohol, and mixtures thereof. When employed, thesefatty alcohol emollients are typically used in combination with thepetroleum-based emollients, such as petrolatum, at a weight ratio offatty alcohol emollient to petroleum-based emollient of from about 1:1to about 1:5, preferably from about 1:1 to about 1:2.

Other suitable types of emollients for use herein include polysiloxanecompounds. In general, suitable polysiloxane materials for use in thepresent invention include those having monomeric siloxane units of thefollowing structure:

wherein, R¹ and R², for each independent siloxane monomeric unit caneach independently be hydrogen or any alkyl, aryl, alkenyl, alkaryl,arakyl, cycloalkyl, halogenated hydrocarbon, or other radical. Any ofsuch radicals can be substituted or unsubstituted. R¹ and R² radicals ofany particular monomeric unit may differ from the correspondingfunctionalities of the next adjoining monomeric unit. Additionally, thepolysiloxane can be either a straight chain, a branched chain or have acyclic structure. The radicals R¹ and R² can additionally independentlybe other silaceous functionalities such as, but not limited tosiloxanes, polysiloxanes, silanes, and polysilanes. The radicals R¹ andR² may contain any of a variety of organic functionalities including,for example, alcohol, carboxylic acid, phenyl, and aminefunctionalities.

Exemplary alkyl radicals are methyl, ethyl, propyl, butyl, pentyl,hexyl, octyl, decyl, octadecyl, and the like. Exemplary alkenyl radicalsare vinyl, allyl, and the like. Exemplary aryl radicals are phenyl,diphenyl, naphthyl, and the like. Exemplary alkaryl radicals are toyl,xylyl, ethylphenyl, and the like. Exemplary aralkyl radicals are benzyl,alpha-phenylethyl, beta-phenylethyl, alpha-phenylbutyl, and the like.Exemplary cycloalkyl radicals are cyclobutyl, cyclopentyl, cyclohexyl,and the like. Exemplary halogenated hydrocarbon radicals arechloromethyl, bromoethyl, tetrafluorethyl, fluorethyl, trifluorethyl,trifluorotloyl, hexafluoroxylyl, and the like.

Viscosity of polysiloxanes useful may vary as widely as the viscosity ofpolysiloxanes in general vary, so long as the polysiloxane is flowableor can be made to be flowable for application to the absorbent article.This includes, but is not limited to, viscosity as low as 5 centistokes(at 37° C. as measured by a glass viscometer) to about 20,000,000centistokes. Preferably the polysiloxanes have a viscosity at 37° C.ranging from about 5 to about 5,000 centistokes, more preferably fromabout 5 to about 2,000 centistokes, most preferably from about 100 toabout 1000 centistokes. High viscosity polysiloxanes which themselvesare resistant to flowing can be effectively deposited upon the absorbentarticles by such methods as, for example, emulsifying the polysiloxanein surfactant or providing the polysiloxane in solution with the aid ofa solvent, such as hexane, listed for exemplary purposes only.Particular methods for applying polysiloxane emollients to absorbentarticles are discussed in more detail hereinafter.

Preferred polysiloxanes compounds for use in the present invention aredisclosed in U.S. Pat. No. 5,059,282 (Ampulski et al), issued Oct. 22,1991, which is incorporated herein by reference. Particularly preferredpolysiloxane compounds for use as emollients in the compositions of thepresent invention include phenyl-functional polymethylsiloxane compounds(e.g., Dow Corning 556 Cosmetic-Grade Fluid: polyphenylmethylsiloxane)and cetyl or stearyl functionalized dimethicones such as Dow 2502 andDow 2503 polysiloxane liquids, respectively. In addition to suchsubstitution with phenyl-functional or alkyl groups, effectivesubstitution may be made with amino, carboxyl, hydroxyl, ether,polyether, aldehyde, ketone, amide, ester, and thiol groups. Of theseeffective substituent groups, the family of groups comprising phenyl,amino, alkyl, carboxyl, and hydroxyl groups are more preferred than theothers; and phenyl-functional groups are most preferred.

Suitable humectants include glycerine, propylene glycol, sorbitol,trihydroxy stearin, and the like.

When present, the amount of emollient that can be included in thecomposition will depend on a variety of factors, including theparticular emollient involved, the skin benefits desired, the othercomponents in the composition and like factors. The composition willcomprise from 0 to about 100%, by total weight, of the emollient.Preferably, the composition will comprise from about 10 to about 95%,more preferably from about 20 to about 80%, and most preferably fromabout 40 to about 75%, by weight, of the emollient.

Another optional, preferred component of the therapeutic/skin protectivecompositions useful in the methods of the present invention is an agentcapable of immobilizing the composition (including the preferredemollient and/or other skin condition/protective agents) in the desiredlocation in or on the treated article. Because certain of the preferredemollients in the composition have a plastic or liquid consistency at20° C., they tend to flow or migrate, even when subjected to modestshear. When applied to a wearer-contacting surface or other location ofan absorbent article, especially in a melted or molten state, theemollient will not remain primarily in or on the treated region.Instead, the emollient will tend to migrate and flow to undesiredregions of the article.

Specifically, if the emollient migrates into the interior of thearticle, it can cause undesired effects on the absorbency of the articlecore due to the hydrophobic characteristics of many of the emollientsand other skin conditioning agents used in the compositions useful inthe methods of the present invention. It also means that much moreemollient has to be applied to the article to get the desiredtherapeutic and/or protective benefits. Increasing the level ofemollient not only increases the cost, but also exacerbates theundesirable effect on the absorbency of the article's core and undesiredtransfer of composition during processing/converting of the treatedarticles.

The immobilizing agent counteracts this tendency of the emollient tomigrate or flow by keeping the emollient primarily localized on thesurface or in the region of the article to which the composition isapplied. This is believed to be due, in part, to the fact that theimmobilizing agent raises the melting point and/or viscosity of thecomposition above that of the emollient. Since the immobilizing agent ispreferably miscible with the emollient (or solubilized in the emollientwith the aid of an appropriate emulsifier), it entraps the emollient onthe surface of the article's wearer contacting surface or in the regionto which it is applied.

The immobilizing agent counteracts this tendency of the emollient tomigrate or flow by keeping the emollient primarily localized on thesurface or in the region of the article to which the composition isapplied. This is believed to be due, in part, to the fact that theimmobilizing agent raises the melting point and/or viscosity of thecomposition above that of the emollient. Since the immobilizing agent ispreferably miscible with the emollient (or solubilized in the emollientwith the aid of an appropriate emulsifier or dispersed therein), itentraps the emollient on the surface of the article's wearer contactingsurface or in the region to which it is applied.

It is also advantageous to “lock” the immobilizing agent on the wearercontacting surface or the region of the article to which it is applied.This can be accomplished by using immobilizing agents which quickly setup (i.e., solidify) upon application to the article. In addition,outside cooling of the treated article via blowers, fans, cold rolls,etc. can speed up crystallization of the immobilizing agent.

In addition to being miscible with (or solubilized in) the emollient,the immobilizing agent will preferably have a melting profile that willprovide a composition that is solid or semisolid at ambient temperature.In this regard, preferred immobilizing agents will have a melting pointof at least about 35° C. This is so the immobilizing agent itself willnot have a tendency to migrate or flow. Preferred immobilizing agentswill have melting points of at least about 40° C. Typically, theimmobilizing agent will have a melting point in the range of from about50° to about 150° C.

When utilized, immobilizing agents useful herein can be selected fromany of a number of agents, so long as the preferred properties of theskin care composition provide the skin benefits described herein.Preferred immobilizing agents will comprise a member selected from thegroup consisting of C₁₄-C₂₂ fatty alcohols, C₁₂-C₂₂ fatty acids, andC₁₂-C₂₂ fatty alcohol ethoxylates having an average degree ofethoxylation ranging from 2 to about 30, and mixtures thereof. Preferredimmobilizing agents include C₁₆-C₁₈ fatty alcohols, most preferablycrystalline high melting materials selected from the group consisting ofcetyl alcohol, stearyl alcohol, behenyl alcohol, and mixtures thereof(The linear structure of these materials can speed up solidification onthe treated absorbent article.) Mixtures of cetyl alcohol and stearylalcohol are particularly preferred. Other preferred immobilizing agentsinclude C₁₆-C₁₈ fatty acids, most preferably selected from the groupconsisting of palmitic acid, stearic acid, and mixtures thereof.Mixtures of palmitic acid and stearic acid are particularly preferred.Still other preferred immobilizing agents include C₁₆-C₁₈ fatty alcoholethoxylates having an average degree of ethoxylation ranging from about5 to about 20. Preferably, the fatty alcohols, fatty acids and fattyalcohols are linear. Importantly, these preferred immobilizing agentssuch as the C₁₆-C₁₈ fatty alcohols increase the rate of crystallizationof the composition causing the composition to crystallize rapidly ontothe surface of the substrate.

Other types of immobilizing agents that may be used herein includepolyhydroxy fatty acid esters, polyhydroxy fatty acid amides, andmixtures thereof. Preferred esters and amides will have three or morefree hydroxy groups on the polyhydroxy moiety and are typically nonionicin character. Because of the possible skin sensitivity of those usingarticles to which the composition is applied, these esters and amidesshould also be relatively mild and non-irritating to the skin.

Suitable polyhydroxy fatty acid esters for use in the present inventionwill have the formula:

wherein R is a C₅-C₃₁ hydrocarbyl group, preferably straight chainC₇-C₁₉ alkyl or alkenyl, more preferably straight chain C₉-C₁₇ alkyl oralkenyl, most preferably straight chain C₁₁-C₁₇ alkyl or alkenyl, ormixture thereof; Y is a polyhydroxyhydrocarbyl moiety having ahydrocarbyl chain with at least 2 free hydroxyls directly connected tothe chain; and n is at least 1. Suitable Y groups can be derived frompolyols such as glycerol, pentaerythritol; sugars such as raffinose,maltodextrose, galactose, sucrose, glucose, xylose, fructose, maltose,lactose, mannose and erythrose; sugar alcohols such as erythritol,xylitol, malitol, mannitol and sorbitol; and anhydrides of sugaralcohols such as sorbitan.

One class of suitable polyhydroxy fatty acid esters for use in thepresent invention comprises certain sorbitan esters, preferably thesorbitan esters of C₁₆-C₂₂ saturated fatty acids. Because of the mannerin which they are typically manufactured, these sorbitan esters usuallycomprise mixtures of mono-, di-, tri-, etc. esters. Representativeexamples of suitable sorbitan esters include sorbitan palmitates (e.g.,SPAN 40), sorbitan stearates (e.g., SPAN 60), and sorbitan behenates,that comprise one or more of the mono-, di- and tri-ester versions ofthese sorbitan esters, e.g., sorbitan mono-, di- and tri-palmitate,sorbitan mono-, di- and tri-stearate, sorbitan mono-, di andtri-behenate, as well as mixed tallow fatty acid sorbitan mono-, di- andtri-esters. Mixtures of different sorbitan esters can also be used, suchas sorbitan palmitates with sorbitan stearates. Particularly preferredsorbitan esters are the sorbitan stearates, typically as a mixture ofmono-, di- and tri-esters (plus some tetraester) such as SPAN 60, andsorbitan stearates sold under the trade name GLYCOMUL-S by Lonza, Inc.Although these sorbitan esters typically contain mixtures of mono-, di-and tri-esters, plus some tetraester, the mono- and di-esters areusually the predominant species in these mixtures.

Another class of suitable polyhydroxy fatty acid esters for use in thepresent invention comprises certain glyceryl monoesters, preferablyglyceryl monoesters of C₁₆-C₂₂ saturated fatty acids such as glycerylmonostearate, glyceryl monopalmitate, and glyceryl monobehenate. Again,like the sorbitan esters, glyceryl monoester mixtures will typicallycontain some di- and triester. However, such mixtures should containpredominantly the glyceryl monoester species to be useful in the presentinvention.

Another class of suitable polyhydroxy fatty acid esters for use in thepresent invention comprise certain sucrose fatty acid esters, preferablythe C₁₂-C₂₂ saturated fatty acid esters of sucrose. Sucrose monoestersand diesters are particularly preferred and include sucrose mono- anddi-stearate and sucrose mono- and di-laurate.

Suitable polyhydroxy fatty acid amides for use in the present inventionwill have the formula:

wherein R¹ is H, C₁-C₄ hydrocarbyl, 2-hydroxyethyl, 2-hydroxypropyl,methoxyethyl, methoxypropyl or a mixture thereof, preferably C₁-C₄alkyl, methoxyethyl or methoxypropyl, more preferably C₁ or C₂ alkyl ormethoxypropyl, most preferably C₁ alkyl (i.e., methyl) or methoxypropyl;and R² is a C₅-C₃₁ hydrocarbyl group, preferably straight chain C₇-C₁₉alkyl or alkenyl, more preferably straight chain C₉-C₁₇ alkyl oralkenyl, most preferably straight chain C₁₁-C₁₇ alkyl or alkenyl, ormixture thereof; and Z is a polyhydroxyhydrocarbyl moiety having alinear hydrocarbyl chain with at least 3 hydroxyls directly connected tothe chain. See U.S. Pat. No. 5,174,927 (Honsa), issued Dec. 29, 1992(herein incorporated by reference) which discloses these polyhydroxyfatty acid amides, as well as their preparation.

The Z moiety preferably will be derived from a reducing sugar in areductive amination reaction; most preferably glycityl. Suitablereducing sugars include glucose, fructose, maltose, lactose, galactose,mannose, and xylose. High dextrose corn syrup, high fructose corn syrup,and high maltose corn syrup can be utilized, as well as the individualsugars listed above. These corn syrups can yield mixtures of sugarcomponents for the Z moiety.

The Z moiety preferably will be selected from the group consisting of—CH₂—(CHOH)_(n)—CH₂OH, —CH(CH₂OH)—[(CHOH)_(n-1)]—CH₂OH,—CH₂OH—CH₂—(CHOH)₂(CHOR³)(CHOH)—CH₂OH, where n is an integer from 3 to5, and R³ is H or a cyclic or aliphatic monosaccharide. Most preferredare the glycityls where n is 4, particularly —CH₂—(CHOH)₄—CH₂OH.

In the above formula, R¹ can be, for example, N-methyl, N-ethyl,N-propyl, N-isopropyl, N-butyl, N2-hydroxyethyl, N-methoxypropyl orN2-hydroxypropyl. R² can be selected to provide, for example, cocamides,stearamides, oleamides, lauramides, myristamides, capricamides,palmitamides, tallowamides, etc. The Z moiety can be 1-deoxyglucityl,2-deoxyfructityl, 1-deoxymaltityl, 1-deoxylactityl, 1-deoxygalactityl,1-deoxymannityl, 1-deoxymaltotriotityl, etc.

The most preferred polyhydroxy fatty acid amides have the generalformula:

wherein R¹ is methyl or methoxypropyl; R² is a C₁₁-C₁₇ straight-chainalkyl or alkenyl group. These include N-lauryl-N-methyl glucamide,N-lauryl-N-methoxypropyl glucamide, N-cocoyl-N-methyl glucamide,N-cocoyl-N-methoxypropyl glucamide, N-palmityl-N-methoxypropylglucamide, N-tallowyl-N-methyl glucamide, or N-tallowyl-N-methoxypropylglucamide.

As previously noted, some of the immobilizing agents may require anemulsifier for solubilization in the emollient. This is particularly thecase for certain of the glucamides such as the N-alkyl-N-methoxypropylglucamides having HLB values of at least about 7. Suitable emulsifierswill typically include those having HLB values below about 7. In thisregard, the sorbitan esters previously described, such as the sorbitanstearates, having HLB values of about 4.9 or less have been found usefulin solubilizing these glucamide immobilizing agents in petrolatum. Othersuitable emulsifiers include steareth-2 (polyethylene glycol ethers ofstearyl alcohol that conform to the formula CH₃(CH₂)₁₇(OCH₂CH₂)_(n)OH,where n has an average value of 2), sorbitan tristearate, isosorbidelaurate, and glyceryl monostearate. The emulsifier can be included in anamount sufficient to solubilize the immobilizing agent in the emollientsuch that a substantially homogeneous mixture is obtained. For example,an approximately 1:1 mixture of N-cocoyl-N-methyl glucamide andpetrolatum that will normally not melt into a single phase mixture, willmelt into a single phase mixture upon the addition of 20% of a 1:1mixture of Steareth-2 and sorbitan tristearate as the emulsifier.

Other types of ingredients that can be used as immobilizing agents,either alone, or in combination with the above-mentioned immobilizingagents, include waxes such as carnauba, ozokerite, beeswax, candelilla,paraffin, ceresin, esparto, ouricuri, rezowax, isoparaffin, and otherknown mined and mineral waxes. The high melt point of these materialscan help immobilize the composition on the desired surface or locationon the article. Addionally microcrystalline waxes are effectiveimmobilizing agents. Microcrystalline waxes can aid in “locking” up lowmolecular weight hydrocarbons within the skin care composition.Preferably the wax is a paraffin wax. An example of a particularlypreferred alternate immobilizing agent is a paraffin wax such asParrafin S.P. 434 from Strahl and Pitsch Inc. P.O. Box 1098 WestBabylon, N.Y. 11704.

The amount of the optional immobilizing agent that can be included inthe composition will depend on a variety of factors, including theactives (e.g., emollients) involved, the particular immobilizing agentinvolved, if any, the other components in the composition, whether anemulsifier is required to solubilize the immobilizing agent in the othercomponents, and like factors. When present, the composition willtypically comprise from about 5 to about 90% of the immobilizing agent.Preferably, the composition will comprise from about 5 to about 50%,most preferably from about 10 to about 40%, of the immobilizing agent.

Of course, it is highly desirable that at least a portion of thearticle's topsheet be made of a hydrophilic material to promote rapidtransfer of liquids (e.g., urine) through the topsheet. Similarly, itmay be desirable that the composition be sufficiently wettable to ensurethat liquids will transfer through the topsheet rapidly. Alternatively,hydrophobic skin care composition may be utilized, so long as they areapplied such that the fluid handling properties of the topsheet areadequately maintained. (For example, as discussed below, nonuniformapplication of the composition to the topsheet is one means toaccomplish this goal.) This diminishes the likelihood that body exudateswill flow off the composition-treated topsheet rather than being drawnthrough the topsheet and being absorbed by the absorbent core. Where ahydrophilic composition is desired, depending upon the particularcomponents used in the composition, a hydrophilic surfactant (or amixture of hydrophilic surfactants) may, or may not, be required toimprove wettability. For example, some immobilizing agents, such asN-cocoyl-N-methoxypropyl glucamide have HLB values of at least about 7and are sufficiently wettable without the addition of hydrophilicsurfactant. Other immobilizing agents such as the C₁₆-C₁₈ fatty alcoholshaving HLB values below about 7 may require addition of hydrophilicsurfactant to improve wettability when the composition is applied toarticle topsheets. Similarly, a hydrophobic emollient such as petrolatummay require the addition of a hydrophilic surfactant if hydrophiliccomposition is desired. Of course, the concern around wettability is nota factor when the wearer-contacting surface under consideration is otherthan the article's topsheet or when fluid handling properties of thetopsheet are adequately maintained via other means (e.g., nonuniformapplication).

Suitable hydrophilic surfactants will preferably be miscible with theother components of the skin care composition so as to form blendedmixtures. Because of possible skin sensitivity of those using disposableabsorbent products to which the composition is applied, thesesurfactants should also be relatively mild and non-irritating to theskin. Typically, these hydrophilic surfactants are nonionic to be notonly non-irritating to the skin, but also to avoid other undesirableeffects on any other structures within the treated article. For example,reductions tissue laminate tensile strength, adhesive bondsufficiencies, and the like.

Suitable nonionic surfactants may be substantially nonmigratory afterthe composition is applied to the articles and will typically have HLBvalues in the range of from about 4 to about 20, preferably from about 7to about 20. To be nonmigratory, these nonionic surfactants willtypically have melt temperatures greater than the temperatures commonlyencountered during storage, shipping, merchandising, and use ofdisposable absorbent products, e.g., at least about 30° C. In thisregard, these nonionic surfactants will preferably have melting pointssimilar to those of the immobilizing agents previously described.

Suitable nonionic surfactants for use in compositions that will beapplied to the articles, at least in the liquid discharge region of thediaper, include alkylglycosides; alkylglycoside ethers as described inU.S. Pat. No. 4,011,389 (Langdon, et al), issued Mar. 8, 1977, which isincorporated by reference; alkylpolyethoxylated esters such asPegosperse 1000 MS (available from Lonza, Inc., Fair Lawn, N.J.),ethoxylated sorbitan mono-, di- and/or tri-esters of C₁₂-C₁₈ fatty acidshaving an average degree of ethoxylation of from about 2 to about 20,preferably from about 2 to about 10, such as TWEEN 60 (sorbitan estersof stearic acid having an average degree of ethoxylation of about 20)and TWEEN 61 (sorbitan esters of stearic acid having an average degreeof ethoxylation of about 4), and the condensation products of aliphaticalcohols with from about 1 to about 54 moles of ethylene oxide. Thealkyl chain of the aliphatic alcohol is typically in a straight chain(linear) configuration and contains from about 8 to about 22 carbonatoms. Particularly preferred are the condensation products of alcoholshaving an alkyl group containing from about 11 to about 22 carbon atomswith from about 2 to about 30 moles of ethylene oxide per mole ofalcohol. Examples of such ethoxylated alcohols include the condensationproducts of myristyl alcohol with 7 moles of ethylene oxide per mole ofalcohol, the condensation products of coconut alcohol (a mixture offatty alcohols having alkyl chains varying in length from 10 to 14carbon atoms) with about 6 moles of ethylene oxide. A number of suitableethoxylated alcohols are commercially available, including TERGITOL15-S-9 (the condensation product of C₁₁-C₁₅ linear alcohols with 9 molesof ethylene oxide), marketed by Union Carbide Corporation; KYRO EOB(condensation product of C₁₃-C₁₅ linear alcohols with 9 moles ofethylene oxide), marketed by The Procter & Gamble Co., the NEODOL brandname surfactants marketed by Shell Chemical Co., in particular NEODOL25-12 (condensation product of C₁₂-C₁₅ linear alcohols with 12 moles ofethylene oxide) and NEODOL 23-6.5T (condensation product of C₁₂-C₁₃linear alcohols with 6.5 moles of ethylene oxide that has been distilled(topped) to remove certain impurities), and especially the PLURAFACbrand name surfactants marketed by BASF Corp., in particular PLURAFACA-38 (a condensation product of a C₁₈ straight chain alcohol with 27moles of ethylene oxide). (Certain of the hydrophilic surfactants, inparticular ethoxylated alcohols such as NEODOL 25-12, can also functionas alkyl ethoxylate emollients). Other examples of preferred ethoxylatedalcohol surfactants include ICI's class of Brij surfactants and mixturesthereof, with Brij 72 (i.e., Steareth-2) and Brij 76 (i.e., Steareth-10)being especially preferred. Also, mixtures of cetyl alcohol and stearylalcohol ethoxylated to an average degree of ethoxylation of from about10 to about 20 may also be used as the hydrophilic surfactant.

Another type of suitable surfactant for use in the composition includesAerosol OT, a dioctyl ester of sodium sulfosuccinic acid marketed byAmerican Cyanamid Company.

Still another type of suitable surfactant for use in the compositionincludes silicone copolymers such as General Electric SF 1188 (acopolymer of a polydimethylsiloxane and a polyoxyalkylene ether) andGeneral Electric SF 1228 (a silicone polyether copolymer). Thesesilicone surfactants can be used in combination with the other types ofhydrophilic surfactants discussed above, such as the ethoxylatedalcohols. These silicone surfactants have been found to be effective atconcentrations as low as 0.1%, more preferably from about 0.25 to about1.0%, by weight of the composition.

Where a hydrophilic composition is desired, the amount of hydrophilicsurfactant required to increase the wettability of the composition to adesired level will depend in-part upon the HLB value and level ofimmobilizing agent, if any, used, the HLB value of the surfactant usedand like factors. The composition can comprise from about 0.1 to about50% of the hydrophilic surfactant when needed to increase thewettability properties of the composition. Preferably, the compositioncomprises from about 1 to about 25%, most preferably from about 10 toabout 20%, of the hydrophilic surfactant when needed to increasewettability.

Compositions can comprise other components typically present inemulsions, creams, ointment, lotions, powders, suspensions, etc. of thistype. These components include water, viscosity modifiers, perfumes,disinfectant antibacterial actives, antiviral agents, vitamins,pharmaceutical actives, film formers, deodorants, opacifiers,astringents, solvents, preservatives, and the like. In addition,stabilizers can be added to enhance the shelf life of the compositionsuch as cellulose derivatives, proteins and lecithin. All of thesematerials are well known in the art as additives for such formulationsand can be employed in appropriate amounts in the compositions for useherein.

If water-based skin care compositions are used, a preservative will beneeded. Suitable preservatives include propyl paraben, methyl paraben,benzyl alcohol, benzylkonnium, tribasic calcium phosphate, BHT, or acidssuch as citric, tartaric, maleic, lactic, malic, benzoic, salicylic, andthe like. Suitable viscosity increasing agents include some of theagents described as effective immobilizing agents. Other suitableviscosity increasing agents include alkyl galactomannan, silica, talc,magnesium silicate, sorbitol, colloidal silicone dioxide, magnesiumaluminum silicate, zinc stearate, wool wax alcohol, sorbiton,sesquioleate, cetyl hydroxy ethyl cellulose and other modifiedcelluloses. Suitable solvents include propylene glycol, glycerine,cyclomethicone, polyethylene glycols, hexylene glycol, diol andmulti-hydroxy based solvents. Suitable vitamins include A, D-3, E, B-5and E acetate.

IV. Absorbent Articles

As used herein, the term “absorbent article” refers to a device whichabsorbs and retains body exudates. The term “disposable” is used hereinto describe absorbent articles which are not intended to be laundered orotherwise restored or reused as an absorbent article after a single use.Examples of disposable absorbent articles include feminine hygienegarments such as sanitary napkins, panti-liners and tampons, diapers,incontinence briefs, diaper holders, training pants, and the like.

Disposable absorbent articles typically comprise a liquid pervioustopsheet, a liquid impervious backsheet and an absorbent core positionedbetween the topsheet and the backsheet. Disposable absorbent articlesand components thereof, including the topsheet, backsheet, absorbentcore, and any individual layers of these components, have a body facingsurface and a garment facing surface. As used herein, “body facingsurface” means that surface of the article or component which isintended to be worn toward or adjacent to the body of the wearer, whilethe “garment facing surface” is on the opposite side and is intended tobe worn toward or placed adjacent to the wearer's clothing orundergarments when the disposable absorbent article is worn.

The following description generally discusses the absorbent core,topsheet, and backsheet materials that are useful in disposableabsorbent articles that are used in the methods of the presentinvention. It is to be understood that this general description appliesto these components of the specific absorbent articles shown in FIG. 1and further described below, in addition to those of other disposableabsorbent articles which are generally described herein.

In general, the absorbent core is capable of absorbing or retainingliquids (e.g., menses, urine, and/or other body exudates). The absorbentcore is preferably compressible, conformable, and non-irritating to thewearer's skin. The absorbent core may be manufactured in a wide varietyof sizes and shapes (e.g., rectangular, oval, hourglass, “T” shaped, dogbone, asymmetric, etc.). In addition to the absorbent composites of thepresent invention, the absorbent core may include any of a wide varietyof liquid-absorbent materials commonly used in absorbent articles, suchas comminuted wood pulp, which is generally referred to as airfelt.Examples of other suitable absorbent materials for use in the absorbentcore include creped cellulose wadding; meltblown polymers includingconform; chemically stiffened, modified or cross-linked cellulosicfibers; synthetic fibers such as crimped polyester fibers; peat moss;tissue including tissue wraps and tissue laminates; absorbent foams;absorbent sponges; superabsorbent polymers; absorbent gelling materials;or any equivalent material or combinations of materials, or mixtures ofthese.

The configuration and construction of the absorbent core may also bevaried (e.g., the absorbent core may have varying caliper zones and/orhave a profile so as to be thicker in the center; hydrophilic gradients;gradients of the absorbent composite of the present invention,superabsorbent gradients; or lower average density and lower averagebasis weight zones, e.g., acquisition zones; or may comprise one or morelayers or structures). The total absorbent capacity of the absorbentcore should, however, be compatible with the design loading and theintended use of the absorbent article. Further, the size and absorbentcapacity of the absorbent core may be varied to accommodate differentuses such as diapers, incontinence pads, pantiliners, regular sanitarynapkins, and overnight sanitary napkins, and to accommodate wearersranging from infants to adults.

The absorbent core can include other absorbent components that are oftenused in absorbent articles, for example, a dusting layer, a wicking oracquisition layer, or a secondary topsheet for increasing the wearer'scomfort.

The topsheet is preferably compliant, soft feeling, and non-irritatingto the wearer's skin. Further, the topsheet is liquid pervious,permitting liquids (e.g., menses and/or urine) to readily penetratethrough its thickness. A suitable topsheet may be manufactured from awide range of materials such as woven and nonwoven materials (e.g., anonwoven web of fibers), including apertured nonwovens; polymericmaterials such as apertured formed thermoplastic films, aperturedplastic films, and hydroformed thermoplastic films; porous foams;reticulated foams; reticulated thermoplastic films; and thermoplasticscrims. Suitable woven and nonwoven materials can be comprised ofnatural fibers (e.g., wood or cotton fibers), synthetic fibers (e.g.,polymeric fibers such as polyester, polypropylene, or polyethylenefibers) or from a combination of natural and synthetic fibers. When thetopsheet comprises a nonwoven web, the web may be manufactured by a widenumber of known techniques. For example, the web may be spunbonded,spunlace carded, wet-laid, melt-blown, hydroentangled, hydroformed,hydroapertured, combinations of the above, or the like.

The backsheet is impervious to liquids (e.g., menses and/or urine) andis preferably comprises a thin plastic film, although other flexibleliquid impervious materials may also be used. As used herein, the term“flexible” refers to materials which are compliant and will readilyconform to the general shape and contours of the human body. Thebacksheet prevents the exudates absorbed and contained in the absorbentcore from wetting articles which contact the absorbent article such asbedsheets, pants, pajamas and undergarments. The backsheet may thuscomprise a woven or nonwoven material, polymeric films such asthermoplastic films of polyethylene or polypropylene, or compositematerials such as a film-coated nonwoven material.

The backing materials or outer covers of diapers have traditionally beenmade from plastic films due to cost considerations and the liquidimpermeable nature of plastic films. While plastic films are efficientat containing liquids and other waste matters during use, the sameplastic films have certain disadvantages in that they are not pleasingto the touch and they do not readily pass water vapor so that, from awearer wellness standpoint, plastic films tend to cause skin hydrationthereby making infants more prone to diaper rash. One solution has beento supplant normal nonporous plastic films with breathable plastic filmsas the diaper backing materials. For the purposes of the presentinvention, a film is “breathable” if it has a water vapor transmissionrate of at least 100 g/m²/24 hours as calculated using the test methodoutlined below with respect to the examples. Polyolefin films are oftenused for making breathable films. A particularly useful film for suchapplication is made from a linear polyolefin containing organic and/orinorganic fillers. Such filled polyolefin films provide good water vaportransmission thereby making the diapers more comfortable to the wearer.As a result, the relative humidity and temperature within the diaper orother product can be reduced by using breathable materials. Despitethis, such breathable films have the disadvantage of being cold andclammy because breathable films pass moisture to the outside of theproduct where it condenses readily on the film surface. Consequently,another solution has been to attempt to use nonwoven materials as thebacking material for diapers. Fibrous nonwoven webs when used as thebacking material for diapers alleviate the above-mentioned filmproblems, however, such fibrous nonwoven webs generally provide poorbarriers to the passage of liquids including urine. In view of theforegoing deficiencies of both films and fibrous nonwovens, attemptshave been made to combine the two materials thereby making it possibleto rely upon the strengths of one material to overcome the weaknesses ofthe other.

A suitable backsheet is a polyethylene film having a thickness of fromabout 0.012 mm (0.5 mil) to about 0.051 mm (2.0 mils). Exemplarypolyethylene films are manufactured by Clopay Corporation of Cincinnati,Ohio, under the designation P18-1401 and by Tredegar Film Products ofTerre Haute, Ind., under the designation XP-39385. The backsheet ispreferably embossed and/or matte finished to provide a more clothlikeappearance. The size of the backsheet is dictated by the size of theabsorbent core and the exact absorbent article design selected.

As discussed above, while it is preferred that the composition which iscontinually, automatically transferred to the wearer's skin by wearingarticles described herein be relatively impervious to liquids such asurine and runny feces, it is also preferred that the composition berelatively vapor pervious to provide a nonocclusive barrier for theskin. In this regard, to further facilitate the maintenance orimprovement of skin health, uncompromised skin in the wearer's regionunder the absorbent article via the presently disclosed methods,preferred absorbent articles useful in those methods are those whichalso provide “breathability”, to facilitate relatively lower relativehumidity in the area between the skin and the absorbent article.Recently, attempts have been disclosed that are directed to improvingwearer skin condition by allowing the overhydrated skin to dehydrate toan acceptable level by allowing either air to reach the skin (thusminimizing potential occlusion effects) and/or providing means forremoving water vapor from the surface of the skin. Generally, suchmechanisms are referred to as “breathability” or “vapor or moisturepermeability”. Specific examples include feminine hygiene products, suchas catamenial products or so-called pantiliners as described inEP-A-0.104.906; EP-A-0.171.041; EP-A-0.710.471; the disclosure of eachof which is incorporated herein by reference. Such products generallyhave relatively low liquid storage capacity when compared, for example,to baby diapers or adult incontinence products, which have theoreticalstorage capacities more than ten times the capacity of a femininehygiene product. The “breathable” articles described in these referencesmay be treated with skin care composition as described herein, and suchtreated articles may be useful in the methods of the present invention.

Such breathable materials can be various kinds of webs, such as filmswhich are rendered air/vapor pervious by aperturing as described in U.S.Pat. No. 5,628,737, which issued in the name of Dobrin, et al. on May13, 1997, or by exploiting the “microporosity” property as described inEP-A-0.238.200; EP-A-0.288.021; EP-A-0.352.802; EP-A-0.515.501; U.S.Pat. No. 4,713,068, whereby small voids are created within the filmsimilar to very small cracks. WO 94/23107; WO 94/28224; U.S. Pat. No.4,758,339 which issued in the name of Yeo, et al. on Jul. 19, 1988; andEP-A-0.315.013 all describe alternative breathable materials which canbe fibrous textile or non-woven webs, with air/vapor easily penetratingthrough the relatively large pores of the structure. Such webs, beingeither treated or untreated with regard to improving their liquidimpermeability properties, such as described in EP-A-0.196.654. In WO95/16562 a laminate of a non-woven with a breathable film is disclosed.Further disclosures such as in WO 95/16746 relate to other materialsallowing water molecules to diffuse through. Also, combinations ofvarious materials comprising various layers of any of the above elementsare also well known. Absorbent articles using any of the approachesdescribed in these references (each of which is incorporated herein byreference) in combination with delivering a composition as describedherein may be used to carry out the methods of the present invention.Indeed, a particularly preferred absorbent article for use in thepresent methods is described in detail in U.S. Pat. No. 6,107,537,issued to Elder et al. on Aug. 22, 2000, the disclosure of which isincorporated herein by reference.

The backsheet and the topsheet are positioned adjacent the garmentfacing surface and the body facing surface, respectively, of theabsorbent core. The absorbent core is preferably joined with thetopsheet, the backsheet, or both in any manner as is known by attachmentmeans (not shown in FIG. 1) such as those well known in the art.However, embodiments of the present invention are envisioned whereinportions or the entire absorbent core are unattached to either thetopsheet, the backsheet, or both.

For example, the backsheet and/or the topsheet may be secured to theabsorbent core or to each other by a uniform continuous layer ofadhesive, a patterned layer of adhesive, or an array of separate lines,spirals, or spots of adhesive. Adhesives which have been found to besatisfactory are manufactured by H. B. Fuller Company of St. Paul, Minn.under the designation HL-1258 or H-2031. The attachment means willpreferably comprise an open pattern network of filaments of adhesive asis disclosed in U.S. Pat. No. 4,573,986, issued to Minetola, et al. onMar. 4, 1986, and which is incorporated herein by reference. Anexemplary attachment means of an open pattern network of filamentscomprises several lines of adhesive filaments swirled into a spiralpattern such as illustrated by the apparatus and method shown in U.S.Pat. No. 3,911,173 issued to Sprague, Jr. on Oct. 7, 1975; U.S. Pat. No.4,785,996 issued to Zwieker, et al. on Nov. 22, 1978; and U.S. Pat. No.4,842,666 issued to Werenicz on Jun. 27, 1989. Each of these patents areincorporated herein by reference. Alternatively, the attachment meansmay comprise heat bonds, pressure bonds, ultrasonic bonds, dynamicmechanical bonds, or any other suitable attachment means or combinationsof these attachment means as are known in the art.

A preferred disposable absorbent article in which the wearer contactingsurface is treated with a composition are diapers. As used herein, theterm “diaper” refers to an absorbent article generally worn by infants,and incontinent persons, that is worn about the lower torso of thewearer. In other words, the term “diaper” includes infant diapers,training pants, adult incontinence devices, etc.

FIG. 1 is a plan view of the diaper 50 useful in the methods of thepresent invention in its flat-out, uncontracted state (i.e., withelastic induced contraction pulled out) with portions of the structurebeing cut-away to more clearly show the construction of the diaper 50and with the portion of the diaper 50 which faces away from the wearer(the outer surface) oriented towards the viewer. As shown in FIG. 1, thediaper 50 preferably comprises a liquid pervious topsheet 520; a liquidimpervious backsheet 530 joined with the topsheet 520; an absorbent core540 positioned between the topsheet 520 and the backsheet 530, theabsorbent core 540 having a garment facing surface 542, a body facingsurface 544, side edges 546, waist edges 548, and ears 549. The diaper50 preferably further comprises elasticized leg cuffs 550; an elasticwaist feature multiply designated as 560; and a fastening systemgenerally multiply designated as 570.

The diaper 50 is shown in FIG. 1 to have an outer surface 52, an innersurface 54 corresponding to the body facing surface which is opposed tothe outer surface 52, a first waist region 56, a second waist region 58,and a periphery 51 which is defined by the outer edges of the diaper 50in which the longitudinal edges are designated 55 and the end edges aredesignated 57. (While the skilled artisan will recognize that a diaperis usually described in terms of having a pair of waist regions and acrotch region between the waist regions, in this application, forsimplicity of terminology, the diaper 50 is described as having onlywaist regions including a portion of the diaper which would typically bedesignated as part of the crotch region). The body facing surface 54 ofthe diaper 50 comprises that portion of the diaper 50 which ispositioned adjacent to the wearer's body during use. The body facingsurface 54 generally is formed by at least a portion of the topsheet 520and other components that may be joined to the topsheet 520, such as legcuffs 550, as well as any regions to which the topsheet may not extendbut which still contact the wearer, such as the waist feature 560, sidepanels and the like. The outer surface 52 comprises that portion of thediaper 50 which is positioned away from the wearer's body (i.e., theouter surface 52 generally is formed by at least a portion of thebacksheet 530 and other components that may be joined to the backsheet530). The first waist region 56 and the second waist region 58 extend,respectively, from the end edges 57 of the periphery 51 to the lateralcenterline 53 of the diaper 50. FIG. 1 also shows the longitudinalcenterline 59.

FIG. 1 shows a preferred embodiment of the diaper 50 in which thetopsheet 520 and the backsheet 530 have length and width dimensionsgenerally larger than those of the absorbent core 540. The elasticizedleg cuffs 550 and the backsheet 530 extend beyond the edges of theabsorbent core 540 to thereby form the periphery 51 of the diaper 50.

Diapers of the present invention can have a number of well knownconfigurations, with the absorbent cores thereof being adapted to thepresent invention. Exemplary configurations are described generally inU.S. Pat. No. 3,860,003 issued to Buell on Jan. 14, 1975; U.S. Pat. No.5,151,092 issued to Buell et al. on Sep. 29, 1992; U.S. Pat. No.5,221,274 issued to Buell et al. on Jun. 22, 1993. Each of these patentsis incorporated herein by reference. Another diaper configuration towhich the present invention can be readily adapted are described inco-pending U.S. patent application Ser. No. 08/203,456; filed on Feb.28, 1994 and incorporated herein by reference. The absorbent cores ofdiapers described in these patents can be adapted in light of theteachings herein to include the absorbent composite of the presentinvention as an absorbent gelling material described therein.

A topsheet 520 which is particularly suitable for use in the diaper 50,is carded and thermally bonded by means well known to those skilled inthe fabrics art. A satisfactory topsheet for the present inventioncomprises staple length polypropylene fibers having a denier of about2.2 As used herein, the term “staple length fibers” refers to thosefibers having a length of at least about 15.9 mm (0.625 inches).Preferably, the topsheet has a basis weight from about 14 to about 25grams per square meter. A suitable topsheet is manufactured by Veratec,Inc., a Division of International Paper Company, of Walpole, Mass. underthe designation P-8.

The topsheet 520 of diaper 50 is preferably made of a hydrophilicmaterial to promote rapid transfer of liquids (e.g., urine) through thetopsheet. If the topsheet is made of a hydrophobic material, at leastportions of the upper surface of the topsheet are treated to behydrophilic so that liquids will transfer through the topsheet morerapidly. This diminishes the likelihood that body exudates will flow offthe topsheet rather than being drawn through the topsheet and beingabsorbed by the absorbent core. The topsheet can be rendered hydrophilicby treating it with a surfactant. Suitable methods for treating thetopsheet with a surfactant include spraying the topsheet material withthe surfactant and immersing the material into the surfactant. A moredetailed discussion of such a treatment and hydrophilicity is containedin U.S. Pat. No. 4,988,344 entitled “Absorbent Articles with MultipleLayer Absorbent Layers” issued to Reising, et al on Jan. 29, 1991 andU.S. Pat. No. 4,988,345 entitled “Absorbent Articles with RapidAcquiring Absorbent Cores” issued to Reising on Jan. 29, 1991, each ofwhich is incorporated by reference herein.

Alternatively, the topsheet may be in the form of an apertured formedfilm, which is preferred in feminine hygiene absorbent articles.Apertured formed films are useful because they are pervious to bodyliquids and yet non-absorbent and have a reduced tendency to allowliquids to pass back through and rewet the wearer's skin. Thus, thesurface of the formed film that is in contact with the body remains dry,thereby reducing body soiling and creating a more comfortable feel forthe wearer. Suitable formed films are described in U.S. Pat. No.3,929,135 (Thompson), issued Dec. 30, 1975; U.S. Pat. No. 4,324,246(Mullane et al.), issued Apr. 13, 1982; U.S. Pat. No. 4,342,314 (Radel.et al.), issued Aug. 3, 1982; U.S. Pat. No. 4,463,045 (Ahr et al.),issued Jul. 31, 1984; and U.S. Pat. No. 5,006,394 (Baird), issued Apr.9, 1991. Each of these patents are incorporated herein by reference.Particularly preferred microapertured formed film topsheets aredisclosed in U.S. Pat. No. 4,609,518 (Curro et al), issue Sep. 2, 1986and U.S. Pat. No. 4,629,643 (Curro et al), issued Dec. 16, 1986, whichare incorporated by reference. The preferred topsheet for use infeminine hygiene products is the formed film described in one or more ofthe above patents and marketed on sanitary napkins by The Procter &Gamble Company of Cincinnati, Ohio as “DR1-WEAVE®.”

The body facing surface of the formed film topsheet can be hydrophilicso as to help body liquids to transfer through the topsheet faster thanif the body surface was not hydrophilic so as to diminish the likelihoodthat liquid will flow off the topsheet rather than flowing into andbeing absorbed by the absorbent structure. In a preferred embodiment,surfactant is incorporated into the polymeric materials of the formedfilm topsheet such as is described in U.S. patent Application Ser. No.07/794,745, “Absorbent Article Having A Nonwoven and Apertured FilmCoversheet” filed on Nov. 19, 1991 by Aziz, et al., which isincorporated by reference. Alternatively, the body facing surface of thetopsheet can be made hydrophilic by treating it with a surfactant suchas is described in the above referenced U.S. Pat. No. 4,950,254,incorporated herein by reference.

In a preferred embodiment of a diaper as described herein, the backsheet530 has a modified hourglass shape extending beyond the absorbent core aminimum distance of about 1.3 cm to about 6.4 cm (about 0.5 to about 2.5inch) around the entire diaper periphery.

The absorbent core 540 may take on any size or shape that is compatiblewith the diaper 50. One preferred embodiment of the diaper 50 has anasymmetric, modified T-shaped absorbent core 540 having ears in thefirst waist region but a generally rectangular shape in the second waistregion. Exemplary absorbent materials for use as the absorbent core ofarticles useful in the present methods are described, e.g., in U.S. Pat.No. 4,610,678 entitled “High-Density Absorbent Structures” issued toWeisman et al. on Sep. 9, 1986; U.S. Pat. No. 4,673,402 entitled“Absorbent Articles With Dual-Layered Cores” issued to Weisman et al. onJun. 16, 1987; U.S. Pat. No. 4,888,231 entitled “Absorbent Core Having ADusting Layer” issued to Angstadt on Dec. 19, 1989; and U.S. Pat. No.4,834,735, entitled “High Density Absorbent Members Having Lower Densityand Lower Basis Weight Acquisition Zones”, issued to Alemany et al. onMay 30, 1989. The absorbent core may further comprise the dual coresystem containing an acquisition/distribution core of chemicallystiffened fibers positioned over an absorbent storage core as detailedin U.S. Pat. No. 5,234,423, entitled “Absorbent Article With ElasticWaist Feature and Enhanced Absorbency” issued to Alemany et al., on Aug.10, 1993; and in U.S. Pat. No. 5,147,345, entitled “High EfficiencyAbsorbent Articles For Incontinence Management” issued to Young, LaVonand Taylor on Sep. 15, 1992. All of these patents are incorporatedherein by reference.

In a preferred embodiment, the diaper 50 further comprises elasticizedleg cuffs 550 for providing improved containment of liquids and otherbody exudates; an elastic waist feature 560 that provides improved fitand containment; and a fastening system 570 which forms a side closurewhich maintains the first waist region 56 and the second waist region 58in an overlapping configuration such that lateral tensions aremaintained around the circumference of the diaper to maintain the diaperon the wearer. The diaper 50 may also comprise elasticized waist bands(not shown) and/or elasticized side panels (also not shown) in the waistregions 56 and 58 to provide an elastically extensible feature thatprovides a more comfortable and contouring fit and more effectiveapplication of the diaper 50.

The elasticized leg cuffs 550 can be constructed in a number ofdifferent configurations, including those described in U.S. Pat. Nos.3,860,003; 4,909,803, issued to Aziz et al. on Mar. 20, 1990; U.S. Pat.No. 4,695,278, issued to Lawson on Sep. 22, 1987; and U.S. Pat. No.4,795,454, issued to Dragoo on Jan. 3, 1989, each being incorporatedherein by reference.

Absorbent articles having elasticized cuffs that are treated with acomposition that may be useful herein are disclosed in U.S. Pat. No.6,156,024, issued to Schulte et al. on Dec. 5, 2000, and U.S. patentapplication Ser. No. 08/840,039 (now abandoned), both of which areincorporated by reference.

The elasticized waist feature preferably comprises an elasticizedwaistband (not shown) that may be constructed in a number of differentconfigurations including those described in U.S. Pat. No. No. 4,515,595issued to Kievit et al. on May 7, 1985; U.S. Pat. No. 5,026,364 issuedto Robertson on Jun. 25, 1991; and the above referenced U.S. Pat. No.5,151,092 issued to Buell et al. on Sep. 29, 1992, each of thesereferences being incorporated herein by reference.

The elasticized side panels may be constructed in a number ofconfigurations. Examples of diapers with elasticized side panelspositioned in the ears (ear flaps) of the diaper are disclosed in U.S.Pat. No. 4,857,067, issued to Wood, et al. on Aug. 15, 1989; U.S. Pat.No. 4,381,781, issued to Sciaraffa, et al. on May 3, 1983; U.S. Pat. No.4,938,753, issued to Van Gompel, et al. on Jul. 3, 1990; and U.S. Pat.No. 5,151,092, issued to Buell et al. on Sep. 29, 1992; each of whichare incorporated herein by reference.

Exemplary fastening systems 570 are disclosed in U.S. Pat. No.4,846,815, issued to Scripps on Jul. 11, 1989; U.S. Pat. No. 4,894,060,issued to Nestegard on Jan. 16, 1990; U.S. Pat. No. 4,946,527, issued toBattrell on Aug. 7, 1990; U.S. Pat. No. 3,848,594, issued to Buell onNov. 19, 1974; U.S. Pat. No. B1 4,662,875, issued to Hirotsu et al. onMay 5, 1987; and U.S. Pat. No. 5,151,092, issued to Buell et al. on Sep.29, 1992; each of which is incorporated herein by reference.

The diaper 50 is preferably applied to a wearer by positioning one ofthe waist regions of the diaper, preferably the second waist region 58,under the wearer's back and drawing the remainder of the diaper betweenthe wearer's legs so that the other waist region, preferably the firstwaist region 56, is positioned across the front of the wearer. Thefastening system is then applied to effect a side closure.

Of course, it will be recognized that any absorbent article design maybe utilized to carry out the methods of the present invention, so longas skin care composition is applied to the article so as to betransferred to the skin during use. The disclosure above is merely forillustrative purposes.

The methods of the present invention may also employ training pants toeffect delivery of the desired skin care composition. The term “trainingpants”, as used herein, refers to disposable garments having fixed sidesand leg openings designed for infant or adults wearers. Training pants(also referred in the art as “pull on” products) are placed in positionon the wearer by inserting the wearer's legs into the leg openings andsliding the training pant into position about the wearer's lower torso.Suitable training pants are disclosed in U.S. Pat. No. 5,246,433, issuedto Hasse, et al. on Sep. 21, 1993, U.S. Pat. No. 5,569,234, issued toBuell et al. on Oct. 29, 1996, U.S. Pat. No. 4,940,464, issued to VanGompel et al. on Jul. 10, 1990 and U.S. Pat. No. 5,092,861, issued toNomura et al. on Mar. 3, 1992, the disclosure of each of which isincorporated herein by reference.

Another disposable absorbent article for use in the present methods areincontinence articles. The term “incontinence article” refers to pads,undergarments (pads held in place by a suspension system of same type,such as a belt, or the like), inserts for absorbent articles, capacityboosters for absorbent articles, briefs, bed pads, and the likeregardless of whether they are worn by adults or other incontinentpersons. Suitable incontinence articles are disclosed in U.S. Pat. No.4,253,461 issued to Strickland, et al. on Mar. 3, 1981; U.S. Pat. Nos.4,597,760 and 4,597,761 issued to Buell; the above-mentioned U.S. Pat.Nos. 4,704,115; 4,909,802 issued to Ahr, et al.; U.S. Pat. No. 4,964,860issued to Gipson, et al. on Oct. 23, 1990; and in U.S. patentapplication Ser. No. 07/637,090 filed by Noel, et al. on Jan. 3, 1991(PCT Publication No. WO 92/11830 published on Jul. 23, 1992). Thedisclosure of each of these references is incorporated herein.

Another disposable absorbent article for use in the present methods arefeminine hygiene articles, such as sanitary napkins Suitable femininehygiene articles are disclosed in U.S. Pat. No. 4,556,146, issued toSwanson et al. on Dec. 3, 1985, U.S. Pat. No. B1 4,589,876, issued toVan Tilberg on Apr. 27, 1993, U.S. Pat. No. 4,687,478, issued to VanTilburg on Aug. 18, 1997, U.S. Pat. No. 4,950,264, issued to Osborn, IIIon Aug. 21, 1990, U.S. Pat. No. 5,009,653, issued to Osborn, III on Apr.23, 1991, U.S. Pat. No. 5,267,992, issued to Van Tilburg on Dec. 7,1993, U.S. Pat. No. 5,389,094, issued to Lavash et al. on Feb. 14, 1995,U.S. Pat. No. 5,413,568, issued to Roach et al. on May 9, 1995, U.S.Pat. No. 5,460,623, issued to Emenaker et al. on Oct. 24, 1995, U.S.Pat. No. 5,489,283, issued Van Tilburg on Feb. 6, 1996, U.S. Pat. No.5,569,231, issued to Emenaker et al. on Oct. 29, 1996, and U.S. Pat. No.5,620,430, issued to Bamber on Apr. 15, 1997, the disclosure of each ofwhich is incorporated by reference herein.

V. Treating Articles With Composition

In preparing absorbent articles to carry out the methods of the presentinvention, the skin care composition is applied such that during wear,at least some portion of the composition will transfer from the treatedarticle to the wearer's skin. That is, skin care composition is eitherapplied directly to one or more wearer contacting surfaces, or isapplied to alternate locations or means such that the skin carecomposition is readily available for transfer from one or more wearercontacting surfaces during use without intervention by theuser/caregiver. (For example, materials positioned beneath the wearercontacting surface, encapsulated compositions, etc.) Of course, toeffectuate delivery of composition to those body regions mostsusceptible to skin disorders, it will be preferred to include thecomposition on the portion of the topsheet and cuffs that will contactthe wearer's buttocks, genitals, intertriginous and anal regions duringwear. Additionally, the composition may be applied to other articleregions for delivery to one or more of the wearer's hips, abdomen, back,waist, sides, thighs, etc. Any of a variety of application methods thatevenly distribute lubricious materials having a molten or liquidconsistency can be used. Suitable methods include spraying, printing(e.g., flexographic printing), coating (e.g., contact slot coating,gravure coating), extrusion, or combinations of these applicationtechniques, e.g. spraying the skin care composition on a rotatingsurface, such as a calender roll, that then transfers the composition tothe desired portion of the article. The skin care composition can alsobe applied as a solid material via any of a variety methods, for exampleextrusion.

When applied to the article's topsheet, the manner of applying thecomposition to the article should be such that the topsheet does notbecome saturated with the composition, at least in the regioncorresponding to the liquid discharge region of the article, if thecomposition is hydrophobic in nature. If the topsheet becomes saturatedwith the composition in the liquid discharge region, there is a greaterpotential for the composition to block the topsheet openings, reducingthe ability of the topsheet to transmit liquid to the underlyingabsorbent core. Also, saturation of the topsheet is not required toobtain the therapeutic and/or protective benefits. Similarly, saturationof other treated article components may not be necessary or desired totransfer sufficient composition for desired skin benefits. Particularlysuitable application methods will apply the composition primarily to theouter surface of the diaper topsheet.

The minimum level of composition to be applied to the article'swearer-contacting surface is an amount effective for providing thetherapeutic and/or protective benefits when the composition is deliveredpursuant to the present methods. The level of composition applied willdepend on various factors, including the article component treated, therelative amount of surface area of the wearer-contacting surface nottreated with the composition, the composition's content and the like. Ingeneral, with compositions that are relatively hydrophobic and are to beapplied to essentially all of the topsheet, the composition ispreferably applied to the article topsheet in an amount ranging fromabout 0.1 mg/m² (0.016 mg/cm²) to about 15 mg/m² (2.33 mg/cm²), morepreferably from about 1 mg/m² (0.16 mg/cm²) to about 10 mg/m² (1.55mg/cm²). It will be recognized that higher levels of skin carecomposition may be applied to other article components where fluidhandling properties are not impacted (e.g., cuffs, waist band, sidepanels, etc.). It will also be recognized that for compositions that arerelatively hydrophilic, higher add-on levels may be used on the topsheetwithout adversely impacting liquid handling properties to anunacceptable degree. Conversely, higher levels of a hydrophiliccomposition may be undesired when applied to components (e.g., cuff,waist) other than the topsheet, to avoid wicking of exudates to theedges of the article which may result in leakage.

Because the composition is preferably substantially immobilized on thesurface of the region treated, relatively small amounts of compositionare needed to impart the desired skin care benefits. Applicants believethat the ability to use low levels to impart the desired skin benefitsis due to the fact that pursuant to the methods described herein,composition is continuously, automatically delivered as articles areworn. As indicated, the ability to use relatively low levels of skincare composition, allows the article's topsheet to maintain its liquidtransfer properties in the liquid discharge region.

The composition can be applied nonuniformly to the wearer contactingsurface of the article. By “nonuniform” it is meant that the amount,location, pattern of distribution, etc. of the composition can vary overthe wearer-contacting surface, and may further vary over specificregions of the article. For example, to maintain the liquid handlingperformance of the topsheet, it may be desired to apply the compositionnonuniformly to the topsheet, particularly if the composition ishydrophobic in nature. In this regard, some portions of the treatedsurface of the article (and regions thereof) can have greater or lesseramounts of composition, including portions of the surface that do nothave any composition on it. When the composition is relativelyhydrophobic, in one such preferred embodiment the surface of thetopsheet will have regions where no composition is applied, particularlyin areas of the topsheet that correspond to the crotch region of thearticle. As used herein, the crotch region of the article is therectangle, defined below, that is centered longitudinally and laterallyabout the article's crotch point. The “crotch point” is determined byplacing the article on a wearer in a standing position and then placingan extensible filament around the legs in a figure eight configuration.The point in the article corresponding to the point of intersection ofthe filament is deemed to be the crotch point of the article. (It isunderstood that the crotch point is determined by placing the absorbentarticle on a wearer in the intended manner and determining where thecrossed filament would contact the article.) With regard to incontinencedevices (e.g., diapers, adult incontinent articles), the length of thecrotch region corresponds to 40% of the absorbent article's total length(i.e., in the y-dimension). With regard sanitary napkins, the length ofthe crotch region corresponds to 80% of the absorbent article's totallength. The width of the crotch region is equivalent to the width of thewidest absorbent core component as measured at the crotch point. (Asused herein, “absorbent core” components are those materials involvedwith acquiring, transporting, distributing and/or storing body liquids.As such, the term absorbent core does not include the topsheet orbacksheet of the absorbent article.) By way of illustration, for anincontinent article having a length of 20 in. and a core width at thecrotch point of 4 in., the crotch region is the rectangle, centered onthe crotch point, having a length of 8 in. and a width of 4 in.

Surprisingly, while the topsheet or other components comprising thecomposition are treated nonuniformly (e.g., microscopic or macroscopicregions where no composition is applied), during wear of the article,the composition is transferred to the wearer even in regions of the skincorresponding to untreated regions within the topsheet or othercomponents. The amount and uniformity of composition transferred to theskin is believed to depend on several factors, including, for example,application pattern of the skin care composition, contact of thewearer's skin to the treated article surface, friction created duringwear time between the wearer's skin and the treated region, warmthgenerated from wearer to enhance the transfer of the composition, thecomposition's properties, the materials which constitute thecomposition, and the like.

Where the composition is applied nonuniformly, any pattern may beutilized, including, for example, application of small droplets(obtained via, e.g., spraying) discrete dots (obtained via, e.g.,gravure printing), stripes that run in the longitudinal or lateraldirection of the article (obtained via contact slot coating), spiralsthat run in the longitudinal or lateral direction, etc., patternedprints, etc. In those embodiments where the topsheet comprises discrete,untreated regions, the percent open area of the region of the topsheetthat corresponds to the crotch region of the article can vary widely.(As referred to herein, the “percent open area” of the topsheet isdetermined by (i) measuring the surface area of the topsheet thatoverlies the crotch region, (ii) measuring the total surface area of theuntreated region(s) in this portion of the topsheet and (iii) dividingthe measurement in (ii) by the measurement in (i). As used herein,“untreated” means a region of the topsheet having less than about 0.01mg/m² (0.0016 mg/cm²) of the composition. In this regard, the percentopen area may be from about 1% to about 99%, from about 5% to about 95%,from about 10% to about 90%, from about 15% to about 85%, from about 20%to about 80%, from about 25% to about 75%, from about 30% to about 70%,or from about 35% to about 65%. The percent open area required toachieve the desired composition effect and the desired liquid handlingproperties of the topsheet will be dictated largely by thecharacteristics of the composition (in particular the composition'scontents and its relative hydrophobicity/hydrophilicy properties). Oneskilled in the art will appreciate that the desired percent open areawill be readily determined through routine experimentation.

In general, with compositions that are relatively hydrophobic and are tobe applied such that regions of the topsheet are not coated with thecomposition, the composition is preferably applied to the articletopsheet in an amount ranging from about 0.05 mg/m² (0.0078 mg/cm²) toabout 35 mg/m² (5.43 mg/cm²), more preferably from about 1 mg/m² (0.16mg/cm²) to about 25 mg/m² (3.88 mg/cm²), still more preferably 4 mg/m²(0.62 mg/cm²) to about 20 mg/m² (3.1 mg/cm²). It will be recognized thatfor compositions that are relatively hydrophilic, higher add-on levelsmay be used without adversely impacting liquid handling properties ofthe topsheet to an unacceptable degree. Of course, for articles havingrelatively high percent open areas in the crotch, greater add-on levelsmay be obtainable without adversely affecting liquid handling by thetopsheet.

In one preferred embodiment for carrying out the present methods, thetopsheet of the articles utilized will comprise stripes of compositionthat run in the article's longitudinal direction. These longitudinalstripes (or spirals) are separated by longitudinal stripes where littleor no composition is applied to the topsheet. In these embodiments, eachstripe of composition will typically have a width of from about 0.1 in.to about 0.75 in., more typically from about 0.1 in. to about 0.5 in.,and the width of the stripes containing no composition will typically befrom about 0.1 in. to about 1 in., more typically from about 0.15 toabout 0.5 in. These ranges are applicable to typical infant diaperdesigns. For larger products such as adult incontinent products, theseranges may be higher.

Skin care composition can also be applied in nonuniform patterns onother article components. In these cases, the open area is calculated bythe rectangle defined by the perimeters of the skin care composition.

The composition can be applied to the article at any point duringassembly. For example, the composition can be applied to the finisheddisposable absorbent product before it has been packaged. Thecomposition can also be applied to a given component (e.g., topsheet,cuffs, sides, waste, etc.), at the converting site or by the materialsupplier, before it is combined with the other raw materials to form afinished disposable absorbent product. Again, the composition can beapplied to other zones of the article such that the composition willmigrate to one or more wearer contacting surfaces during use.

The composition is typically applied from a melt thereof to the article.Since in a preferred embodiment, the composition melts at significantlyabove ambient temperatures, it is usually applied as a heatedcomposition to the article. Typically, the composition is heated to atemperature in the range from about 35° to about 150° C., preferablyfrom 40° to about 100° C., prior to being applied to the article. Oncethe melted composition has been applied to the article, it is allowed tocool and solidify. Preferably, the application process is designed toaid in the cooling/set up of the composition.

In applying compositions to the articles, contact slot coating,spraying, gravure coating, extrusion coating methods are preferred. Onesuch method involves slot coating of the composition on the article'stopsheet after the topsheet is assembled with the other raw materialsinto a finished product.

VI. Test Methods

A. Evaluating Erythema and Rash

1. Test Summary

Two different infant diaper products are evaluated to determine if thereis a difference in the frequency and/or severity of diaper rash and/orerythema in the diaper area in an average infant population associatedwith the use of a test product (i.e., comprising a skin care compositionon one or more wearer contacting surface) over that associated with thecontrol product (an equivalent product, with the exception that itcontains no skin care composition).

2. Investigational Plan

2.1 Study Design

This study is conducted at a qualified clinical research organization(CRO) and should comply with good clinical practices (GCP) guidelines.The study is a randomized, double-blind, parallel group comparisonclinical trial in which both the trained skin grader conducting skinevaluations and the caregivers of the panelists will be unaware of thetreatment assignment of the study participants. A sufficient number ofhealthy infants will be recruited from the general population residingin the geographical area of the clinical site to participate andcomplete this study such that two hundred (200) infants, one hundred(100) per group, complete the study.

Two subject groups will participate in this study. Both groups willinclude healthy infants, each comprising approximately 50% males and 50%females. The two groups will be age and/or diaper size balanced (whenwearing appropriately sized diapers). The two groups will consist ofhealthy infants not taking medications for conditions other than thosethat are routine for that age, such as common cold/flu. All infants willpresent Fitzpatrick scale skin type of I-III, and with no evidence ofserious dermatological conditions (i.e., not atopic). (Fitzpatrick I-IIIskin types facilitate erythema grading.) Some level of erythema anddiaper rash in the diaper region is permissible (defined under exclusioncriteria below).

All infants who meet enrollment criteria will be assigned to use thecontrol product for one week (baseline). At the end of one week, theinfants will be randomly assigned into one of two possible groups: onegroup will remain on the control product for three weeks; the othergroup will use a test product for a period of three weeks. As such, thetotal duration of the test for both control and test product users isfour weeks.

At the point when infants are randomized (Visit 2) into two groups, nofurther use of ointments, creams, lotions, corn starch, or powders willpermitted on the skin in the diaper area during the remaining period ofthe study. The use of soap, water, baby wipes, or cleansing gels ispermitted at diaper changes and baths.

The skin condition of infants will be evaluated at the following times:enrollment into the study (Visit 1); following one week baseline (Visit2); twice per week for three weeks (Visits 3 through 8). Beginning withVisit 2, infants should be evaluated three hours (+/−15 minutes) afterbeing changed into a fresh diaper. (Preferably, this change being thefirst after the overnight diaper.) After Visit 2, subsequent visitsshould occur three to four days apart.

2.2 Procedure:

Visit 1 (Enrollment)

-   -   A. Eligibility will be determined on the basis of the        eligibility requirements listed below.    -   B. Erythema and diaper rash evaluations will be conducted at        four sites in the diaper area (genitals, intertriginous, anal,        and buttocks) to confirm acceptance of the infant into the test.        Referring to FIGS. 2 a, 2 b, 2 c, 2 d, and 2 e, the locations        for grader assessment of erythema and rash are shown. FIG. 2 a        shows the region 10 of the buttocks for assessment in both male        and female subjects. FIG. 2 b shows region 100 of the genital        area of a female subject for assessment of erythema and rash.        FIG. 2 b also shows navel 110 of a subject. For purposes of        assessing erythema and rash in the genital area of a female        subject, the upper portion of region 100, shown as line 100 a,        is approximately 1 inch above the top of the labial aperture.        FIG. 2 c shows region 200 of the genital area of a male subject        for assessment of erythema and rash. FIG. 2 c also shows navel        210 of a subject. For purposes of assessing erythema and rash in        the genital area of a male subject, the upper portion of region        200, shown as line 200 a, is approximately 1 inch above the top        of the base of the penis. FIG. 2 d shows the anal region 300 for        assessment of erythema and rash in both male and female        subjects. FIG. 2 e shows regions 400 of the intertriginous area        of both male and female subjects for assessment.    -   C. The parent/infant receives control product for the one week        baseline.

Visit 2

-   -   A. The infant is brought to the test site wearing a diaper worn        for three hour (+/−15 minutes).    -   B. The parent/infant proceeds to the skin grader for evaluations        of skin erythema and rash at four sites in the diaper area        (genitals, intertriginous, anal, and buttocks).    -   C. The infant is randomized into either the test or control        group and given product and instructions to eliminate other        lotion, creme, etc. use.

Visits 3 through 8

-   -   A. The infant is brought to the test site wearing a diaper worn        for three hour (+/−15 minutes).    -   B. The parent/infant proceeds to the skin grader for evaluations        of skin erythema and rash at four sites in the diaper area        (genitals, intertriginous, anal, and buttocks).    -   C. Compliance with restriction on lotion, etc. is confirmed.

2.3 Study Population

As indicated, at least two hundred (200) infants are expected tocomplete this study. Two subject groups will participate in this study,each group comprising approximately 50% males and 50% females. The twogroups will be age and/or diaper size balanced (when wearingappropriately sized diapers). The study population will consist ofhealthy infants not taking medications for conditions other than thosethat are routine for that age such as common cold/flu, with aFitzpatrick scale skin type of I-III, and no evidence of seriousdermatological conditions (e.g., not atopic). The presence of erythemaand diaper rash is permissible.

2.3.1. Inclusion Criteria

Each Infant must:

-   -   a) have no serious dermatological conditions in the diaper area,    -   b) be full time disposable diaper user,    -   c) have a caregiver willing to not use lotions, creams, powders,        or other skin preparations in the diaper area during the study.

The eligibility of each potential infant is also determined by thecompletion of a medical and dermatological history questionnaire.Subjects will be excluded from this study for one or more of the reasonslisted below under exclusion criteria.

2.3.2 Exclusion Criteria

Babies are excluded from participation in the study if:

-   -   they do not meet the inclusion criteria.    -   at the first visit they have a diaper rash grade >2.5.    -   they have diabetes or chicken pox.    -   they have psoriasis, ichthyosis.    -   at Visit 1, they have a significant eruption in the diaper area        and it is the opinion of the Clinical Research Organization's        Principal Investigator or skin grader that the baby should be        excluded.    -   use medication of any kind (e.g., oral antibiotics, antifungal        agents, corticosteroids taken orally or topically applied to the        skin), which in the opinion of the Clinical Research        Organization's Principal Investigator and/or skin grader may        have an influence on baby's skin in the diaper area.    -   they do not fit the diaper as determined at Visit 1.    -   they have any other medical condition that could compromise the        study.    -   they have experienced diarrhea within the past four days.

2.4 Test Materials

The two treatment groups that will be included in this study are asfollows:

-   -   Test Group: will use diapers having a skin care composition that        is transferred to the wearer during use.    -   Control Group: will use equivalent diapers to the Test Group,        but the diapers have no skin care composition that is        transferred to the wearer during use.

2.5 Randomization and Regimen

Infants will be randomly assigned, using a statistically validrandomization schedule, at Visit 2 to either the test or control productgroup. The groups should be balanced for age or diaper size, sex, anddiaper rash severity (e.g., mild, moderate, severe rash). Twins (ormultiple births) will be assigned to use the same product.

2.6 Regimen & Compliance with Treatment

Each infant should arrive at the investigative site at approximately thesame time of the day for each visit. The infants are expected to weartheir assigned products only.

No ointments, creams, lotions, or powders should be used on the skin inthe diaper area after visit 2. The use of soap, water, baby wipes, orcleansing gels is permitted at diaper changes.

Subjects should come to the site such that when their skin is evaluatedthey will have been wearing a product for three hours (+/−15 minutes).Preferably, this product is the one immediately following the overnightdiaper. In the event of a bowel movement within the 3 hour time frame,the diaper should be changed as needed, and skin evaluation shouldproceed as scheduled.

2.7 Blinding

The test is a randomized, double-blind, parallel group comparisonclinical trial in which a trained skin grader conducting skinevaluations, as well as the caregiver of the panelists, will be unawareof the treatment assignment of the study participants.

2.8 Subject Discontinuation/Termination

In addition to the exclusion criteria, a baby will be dropped from thestudy due to:

-   -   failure to appear for more than one visit,    -   medication that is required which will have a significant effect        on the baby's skin condition in the diaper area,    -   they develop erythema or diaper rash >2.5 during the course of        the study,    -   non-compliance—if they use their own diapers during the study,        or if they use lotion, powders, etc.    -   any illness which the Clinical Research Organization's Principle        Investigator decides may effect the results of the study.

2.9 Observations and/or Measurements

Skin evaluations will be conducted by a trained skin grader who will beblinded as to the assignment of treatments for each subject. The samegrader should be used for all examinations. The grader should beexperienced in evaluating infant skin conditions in the diapered region,especially diaper rash. Preferably, the grader will be a nurse. Thegrader will be separated from the area where the diapers are removed sothat the grader will not see what diapers the babies are wearing.

At each examination period, each baby will be examined for erythemafirst, then diaper rash, at 4 locations on the body (genitals,intertriginous, anal, and buttocks).

Erythema and diaper rash severity will each be evaluated using thegrading scales shown below. A pictorial description of the 4 diaperlocations are shown in FIGS. 2 a through 2 e.

3. Statistical Methods

3.1 Planned Statistical Analyses

For purposes of the present disclosure, evidence of a test productimprovement in rash or erythema is defined as a statistical ornon-statistical (as defined above) difference at: (a) one or more of the4 skin grading locations for the study group as a whole; or (b) one ormore of the 4 skin grading locations for any gender or age or diapersize subset of the study group.

Baseline Visit will be defined as Visit 2; post-baseline visits will bedefined as Visits 3 through 8. For all parameters, separate analyseswill be done for each site. The same analyses will be done on theerythema (i.e., redness) severity grades as for the diaper rash severitygrades. The primary comparison of interest is between the treatmentgroups.

The frequency of diaper rash (or erythema) will be analyzed in two ways.First, the presence of diaper rash (erythema) at any time during thecourse of the study will be evaluated. For each treatment group, thenumber and percentage of infants for which diaper rash (or erythema) waspresent (i.e., diaper rash severity grade is greater than 0 at anypost-baseline visit) and absent (i.e., diaper rash severity grade equals0 for every post-baseline visit) will be calculated. These dichotomoustreatment group responses (i.e., presence and absence) will be analyzedusing a chi-square test. The effects of sex or age or diaper size shouldbe investigated using Mantel-Haenszel statistics or, if appropriate, aweighted least squares or loglinear categorical model.

The second way in which diaper rash (or erythema) frequency will beanalyzed is to evaluate the number of post-baseline visits at whichdiaper rash (or erythema) was present for each subject (i.e., diaperrash grade greater than zero). The number of post-baseline visits withdiaper rash (or erythema) will be analyzed using a loglinear Poissonregression model. The effects of sex or age or diaper size should beinvestigated by incorporating these effects into the model.

Diaper rash (or erythema) severity will be analyzed by evaluatingaverage diaper rash (or erythema) severity over all post-baselinevisits. For each subject, the average of all post-baseline visit diaperrash (or erythema) severity grades will be computed. These averageseverity grades will be analyzed using a one-way analysis of variancemodel. A transformation (e.g., log) may be done prior to analysis toimprove the distributional characteristics of the averages (i.e.,improve the homogeneity of the treatment group variances, improve thenormality of the analysis of variance residuals). Alternatively, anonparametric analog to the one-way analysis of variance may be done(e.g., Wilcoxon's Rank Sum Test) if the analysis of variance residualsdo not adequately fit a normal distribution and/or the treatment groupvariances are not homogenous enough. The effects of sex or age or diapersize should be investigated by incorporating these effects into theanalysis of variance model.

ERYTHEMA GRADING SCALE 0 None Skin is clear (may have some very slightdryness) 0.5 Slight Faint to definite pink in a very small area (<2%)1.0 Mild Faint to definite pink in small area (2-10%) or Definiteredness in very small area (<2%) 1.5 Mild/ Faint to definite pink inlarger area (>10%) or Mod Definite redness in a small area (2-10%) orVery intense redness in very small area (<2%) 2.0 Mod- Definite rednessin larger area (10-50%) or erate Very intense redness in very small area(<2%) w/edema 2.5 Mod/Severe Definite redness in very large area (>50%)or Very intense redness in small area (2-10%) w/edema 3.0 Severe/Veryintense redness in larger area (>10%) w/edema

RASH GRADING SCALE 0 None Skin is clear (may have some very slightdryness and/or a single papule but no erythema) 0.5 Slight Erythema:Faint to definite pink in a very small area (<2%) May also have a singlePapule; and May also have: Skin Integrity: Some very slight dryness 1.0Mild Erythema: Faint to definite pink in small area (2-10%) or Definiteredness in very small area (<2%) and/or Papules: A few scattered papules(2-5) May also have: Skin Integrity: Some slight dryness or scaling 1.5Mild/ Erythema: Faint to definite pink in larger area (>10%) Mod orDefinite redness in a small area (2-10%) or Very intense redness in avery small area (<2%) and/or Papules: Slightly scattered papulescovering a single or multiple areas (<10%) May also have: SkinIntegrity: Moderate dryness or scaling 2.0 Mod- Erythema: Definiteredness in large area (10-50%) or erate Very intense redness in verysmall area (2%) and/or Papules/Pustules: Single to several areas(10-50%) of papules, with 0-5 pustules May also have: Skin Integrity:Some slight desquamation or edema 2.5 Mod/ Erythema: Definite redness invery large area (>50%) Severe or Very intense redness in small area(2-10%) and/or Papules/Pustules: Larger areas (>50%) of multiple papulesor numerous pustules or both and/or May also have: Skin Integrity:Moderate desquamation and edema 3.0 Severe Erythema: Very intenseredness in larger area (>10%) and/or Skin Integrity: severedesquamation, severe edema, erosion and ulceration May also have: Largeareas of numerous confluent papules or Numerous pustules/vesiclesB. Transfer of Skin Care Composition to Wearer's SkinOverview

This method uses a removable skin analog material that is placed on awearer's skin for a controlled period of time. After the skin analog hasbeen removed, it is extracted using an appropriate solvent and theamount of skin care composition deposited thereon is determined usingknown analytical methods. The method is described for use with infantdiapers comprising skin care compositions, as defined herein. One ofskill in the art will recognize the appropriate changes for other skincare compositions, absorbent articles, or wearer types.

Subjects

Approximately equal numbers of male and female infants should beselected using the following inclusion and exclusion criteria.Sufficient infants should be selected to ensure that there are at leastfifteen subjects per condition and transfer time who complete allaspects of the test.

Inclusion Criteria

-   a. Healthy infant-   b. Caregiver willing to not use lotions, creams, powders or other    skin preparations in the diaper area for the duration of the test.-   c. Infants who wear disposable diapers full time-   d. Caregiver willing to give child bath the evening before the study    and not again until after completion of the study-   e. Caregiver will to have child refrain from swimming from the    evening before the study until after completion of the study.-   f. Preferably, infants who have infrequent bowel movements    Exclusion Criteria-   a. The infant has been ill within the last four days-   b. Diarrhea (soft stool) any time during the four days before the    test-   c. Medication which might increase frequency of bowel movements    (e.g., oral antibiotics, anti fungal agents, corticosteroids)-   d. Damaged skin in or around the test site (e.g., from sunburn,    active dermal lesions, or the like)-   e. Known allergies or irritation from adhesive or skin care    ingredients    Materials    In Vivo Transfer

Skin Dermatological Tape—TEGADERM Tape No. 1622W Analog: available from3M Health Cares, St. Paul, MN Sample Glass jar with closure availablefrom VWR Scientific, Container West Chester, PA as catalog Number15900-242 Tape Release Baby powder (comprising only talc and fragrance)Powder available from Johnson & Johnson, New Brunswick, NJ SurgicalAvailable from Best Manufacturing Co., Menlo GA, as Gloves product6005PFM.Extraction and Analysis

Extraction Dichloromethane, available from Sigma-Aldrich of St. SolventLouis, MO as 27056-3 Stearyl alcohol Aldrich 25876-8 1-HexadecanolAldrich 25874-1 Dispensing 10 ml Flask Gas Flame ionization Detector,Hewlett Packard Model 5890 Chromatograph is suitable. Column Capillarycolumn: Chrompack CP Sil-5 CB, 2 meters × 0.25 mm id, 0.12 micron filmthickness fused silica capillary (no substitutions) Instrumental Must beable to reproducibly determine areas of peaks Data System of interest.MethodIn Vivo Transfer

-   -   A. Confirm from the subject's caregiver that the subject has        been bathed within the last 24 hours and that no lotions,        powders, etc. have been applied to the diapered region of the        subject's skin since bathing.    -   B. Wearing the surgical gloves, place the subject on the table        and remove his/her diaper.    -   C. Turn the subject on his/her stomach.    -   D. Remove the release liner from a TEGADERM tape and lightly        brush J&J Baby Powder over the adhesive surface (Wear surgical        gloves, or the like, during application to prevent contamination        of the tape). Provide sufficient powder such that there is a        light coat of powder over all of the tape except the edges.        (This step is done to keep the tape from adhering too        aggressively to the child's skin.).    -   E. FIGS. 3 a and 3 b illustrate placement location for the        TEGADERM tape, shown in those figures as tape 700. Apply the        tape 700 to the child's right buttock. The tape 700 is to be        applied to the highest point on the child's buttock immediately        adjacent to, but not in, the child's gluteal groove. A second        tape 700 may be applied to measure transfer at two time        increments or the effect of an additional diaper. If a second        tape is used, apply the tape 700 on the left buttock using the        procedure described above.    -   F. Change diapers according to the following protocol: 3 hour        transfer time-1 diaper; 6 hour transfer time-2 diapers (change        at 3 hours); 24 hour transfer times ad lib by caregiver. For 24        hour transfer times the following additional instructions are to        be followed:    -   1. Use only water and a washcloth for cleaning the diapered area        for the duration of the test. Do not use baby wipes. Avoid        touching the area around the tapes with hands or any cleaning        implement.    -   2. Do not use skin care products (lotions, ointments, creams,        soap, etc.) for the duration of the test.    -   3. Do not bathe the subject for the duration of the test.    -   4. Use only the test diapers. Record the time of each diaper        change.    -   5. Record the time of any bowel movement and clean the subject        with water and a wash cloth.

-   G. Record the time each diaper was applied for all test diapers.

-   H. Recall the subject near the end of the predetermined transfer    time.

-   I. Remove the test diaper. If the child has had a bowel movement,    the study personnel should remove the tape 700 and discard it (the    subject has then completed the test and data from that subject are    not included in the analysis). If the subject has urinated, the tape    700 will be acceptable for analysis as described below.

-   J Test facility personnel should wear surgical gloves and remove the    tape 700 by grasping the edge of the tape 700 with tweezers and    gently peeling the remaining portion of the tape 700 from the skin.

-   K. Place the used tape 700 in one of the glass jars and close the    lid. Make sure the jar is properly labeled for subsequent sample    identification.

-   L. At the completion of the test collect all of the samples in the    jars for analysis as described below.    Extraction and Analysis

This method is designed for use with the preferred skin carecomposition, the skin care composition of Table 1. One of ordinary skillin the art will recognize what adaptions may be necessary to extract andanalyze the level of other skin care compositions. In principle: 1) oneof the major ingredients of the composition is extracted from the skinanalog using an appropriate solvent; 2) gas chromatographic or otherappropriate quantitative analytical techniques are then used todetermine the level of the major ingredient in the extract; 3) amount ofskin care composition is calculated per unit area based on amount ofmajor ingredient in extract and the area of the tape.

Internal Standard/Extraction Solvent

Prepare an internal standard/extraction solvent by accurately weighing100±2 mg of 1-hexadecanol into a small beaker. Dissolve the1-hexadecanol in dichloromethane and transfer to a 1 liter volumetricflask. Rinse the beaker 3 more times with dichloromethane transferringeach rinse portion to the volumetric flask. Fill the volumetric flask tovolume and mix well. This solution will be used to deliver the internalstandard and extract skin care composition from the tapes. When notbeing used, this container should be kept tightly capped to preventevaporation of solvent.

Calibration Standard

Prepare a calibration standard of known concentration by accuratelyweighing (±0.1 mg) 10±1 mg of the stearyl alcohol into a 100 mlvolumetric flask. Record the weight of stearyl alcohol used. Add theinternal standard/extraction solvent to the flask and mix to dissolve.Fill to volume and mix well. When not being used, this container shouldbe kept tightly capped to prevent evaporation of solvent. This solutionwill be used to determine the relative response of the stearyl alcoholto the 1-hexadecanol internal standard for calibration of theinstrument.

Preparation and Calibration of the Gas Chromatograph

All equipment should be installed, operated and maintained according tomanufacturer's recommendations.

Install the column and check all the gas flows with the column oven at100° C. and the injection port and detector at operating temperatures.The GC will be operated under the following conditions:

-   -   Carrier Gas: Hydrogen (Helium may be used); flow rate 1.5 ml/min    -   Injection Port: 325° C.; Split vent flow 30 ml/min; Septum purge        2 ml/min; straight through liner with glass wool plug;        -   Merlin microseal.    -   Injection volume: 2 μA split    -   FID Detector: 350° C.; set gas flows according to manufacturer        suggestions. Typical gas flows are 400 ml/minute for air, 30        ml/minute for hydrogen and 30 ml/minute for the auxiliary (make        up) gas.    -   Column Oven: 100° C. ramped at 15° C./minute to 325° C.; hold        for 10 minutes

Insure that all connections are tight and leak free. Ignite the detectorand allow it to stabilize. Condition the column at 325° C. for 30minutes. Clean the syringe with dichloromethane as needed. The syringeshould also be rinsed with dichloromethane several times after eachinjection. Make several blank runs with injections of dichloromethane toensure that a good baseline is obtained and that no extraneous peaks arepresent in the chromatogram. If extraneous peaks are present or baselineis not suitable, trouble shoot and correct problem(s).

Calibrate the instrument using the calibration standard preparedpreviously. Consult the data system manufacturer's instructions for theproper sequence of operations. Calculations should be performed in amanner similar to that described in CALCULATIONS below in order toprovide the desired result.

Sample Analysis Procedure

-   1) Remove the lid from the sample jar and add 10 ml of the    extraction solvent/internal standard solution using the dispensing    flask. Replace the cap and swirl the contents to insure that the    tape 700 is not adhering to the sides of the jar and is totally    submersed in solvent. Repeat for all samples.-   2) Allow the samples to sit 16 hours (typically done overnight).-   3) Swirl the contents of the jar to mix. Using a transfer pipette,    transfer an aliquot of the sample extract to a properly labeled    autosampler vial. Cap the vial. Replace jar lid and retain until    analyses are complete. Repeat for all samples.-   4) Place the vials in the autosampler in random order and start the    analyses using the GC conditions described above. The first vial    should be a dichloromethane blank. Several “check” standards should    be placed (about every 20th sample) through out the run to verify    correct operation.-   5) At the completion of the run, check each chromatogram to insure    proper analysis. If a problem is suspected, trouble shoot and    correct. Reanalyze samples as needed.    Calculations

The total micrograms of stearyl alcohol in each sample extract iscalculated based on the relative response of the stearyl alcohol peak tothat of the 1-hexadecanol internal standard. The ratio of the peak areasis multiplied by the relative response factor (determined at time ofinstrument calibration) and the micrograms of internal standard in theextract to yield the total μg of stearyl alcohol in a sample.

Instrument Calibration

Determine the instrumental relative response factor for the stearylalcohol and the internal standard based on the areas of the stearylalcohol and 1-hexadecanol peaks in the calibration standardchromatogram.

${{Response}\mspace{14mu}{factor}\mspace{14mu}\left( R_{f} \right)} = {\frac{{Area}_{inst}}{{weight}_{inst}} \times \frac{{weight}_{sa}}{{Area}_{sa}} \times 10}$where Area_(inst) GC peak area for the internal standard

-   -   Area_(sa) GC peak area for the stearyl alcohol    -   weight_(inst) micrograms of the internal standard used to        prepare internal standard/extraction solvent    -   weight_(sa) micrograms of the stearyl alcohol used to prepare        the calibration standard        Sample Calculations

Calculate the total micrograms of stearyl alcohol in each sample usingthe peak areas from the sample chromatogram in the following equation:

${{Total}\mspace{14mu}\mu_{g}\mspace{14mu}{SA}} = {\frac{{Area}_{sa}}{{Area}_{inst}} \times {Rf} \times \frac{{weight}_{inst}}{100}}$where Area_(inst) GC peak area for the internal standard

-   -   Area_(sa) GC peak area for the stearyl alcohol    -   weight_(inst) micrograms of the internal standard used to        prepare internal standard/extraction solvent

Report amount of skin care composition transferred in mg/cm² where:

${{Composition}\mspace{14mu}{Transferred}} = \frac{0.001 \times {\mu g}\mspace{14mu}{of}\mspace{14mu}{stearyl}\mspace{14mu}{alcohol}}{\left( {{concentration}\mspace{14mu}{of}\mspace{14mu}{stearyl}\mspace{14mu}{alcohol}\mspace{14mu}{in}\mspace{14mu}{composition}} \right) \times \left( {{tape}\mspace{14mu}{area}} \right)}$

For the method described above the concentration of stearyl alcohol inthe composition is 41% and the tape patch measures 4.4 cm×4.4 cm.Composition Transferred=(0.001×μg of stearyl alcohol)/(0.41×4.4 cm×4.4cm)0.000126×μg of stearyl alcohol (mg/cm²)B. Water Vapor Transmission Rate Measurement

The Water Vapor Transmission Rate (WVTR) for the sample materials wascalculated in accordance with ASTM Standard E96-80. Circular samplesmeasuring three inches in diameter were cut from each of the testmaterials and a control which was a piece of CELGUARD® 2500 film fromHoechst Celanese Corporation of Sommerville, N.J. CELGUARD® 2500 film isa microporous polypropylene film. Five samples were prepared for eachmaterial. The test dish was a number 60-1 Vapomoter pan distributed byThwing-Albert Instrument Company of Philadelphia, Pa. One hundredmillimeters of water were poured into each Vapometer pan and individualsamples of the test materials and control material were placed acrossthe open tops of the individual pans. Screw-on flanges were tightened toform a seal along the edges of the pan, leaving the associated testmaterial or control material exposed to the ambient atmosphere over a6.5 centimeter diameter circle having an exposed area of approximately33.17 square centimeters. The pans were placed in a forced air over at100° F. (32° C.) for 1 hour to equilibrate. The oven was a constanttemperature oven with external air circulating through it to preventwater vapor accumulation inside. A suitable forced air oven is, forexample, a Blue M Power-O-Matic 60 oven distributed by Blue M ElectricCompany of Blue Island, Ill. Upon completion of the equilibration, thepans were removed from the oven, weighed and immediately returned to theoven. After 24 hours, the pans were removed from the oven and weighedagain. The preliminary test water vapor transmission rate values werecalculated as follows:Test WVTR=(grams weight loss over 24 hours)×315.5g/m²/24 hrsThe relative humidity within the oven was not specifically controlled.

Under predetermined set conditions of 100° F. (32° C.) an ambientrelative humidity, the WVTR for the CELGUARD® 2500 control has beendetermined to be 5000 grams per square meter for 24 hours. Accordingly,the control sample was run with each test and the preliminary testvalues are corrected to set conditions using the following equation:WVTR=(Test WVTR/control WVTR)×5000 g/m²/24 hrs.(g/m²/24 hrs)VII. Specific Examples

The following are specific illustrations of (a) treating diapertopsheets with skin care compositions and (b) methods of the presentinvention which utilize articles comprising those topsheets. Similarapproaches may be utilized to treat other components for providingtreated articles for use in the present methods.

Example 1 Preparation of an Absorbent Article Having a TopsheetComprising a Skin Care Composition

A. Preparation of Skin Care Composition

A skin care composition (Composition A) is made by mixing the followingmelted (i.e., liquid) components together: Petrolatum (available fromWitco Corp., Greenwich, Conn.), Stearyl Alcohol (available from TheProcter & Gamble Company, Cincinnati, Ohio as CO1897) and aloe extract(available from Madis Botanicals, Inc., South Hackensack, N.J. asVeragel Lipoid in Kaydol). The weight percentages of these componentsare shown in Table I below:

TABLE I Component Weight % Petrolatum 58 Stearyl Alcohol 41 Aloe 1B. Preparation of a Treated Article by Contact Slot Coating

Composition A is placed into a heated tank operating at a temperature of170° F. The composition is subsequently applied with a contactapplicator (using, for example, a Meltex EP45 hot melt adhesiveapplicator head having 5 slots and operating at a temperature of 170°F.) onto the topsheet of an article in a striped pattern where thestripes run in the article's longitudinal direction. Specifically, 5stripes are applied, each stripe measuring 0.25 in. wide (i.e., in thearticles lateral direction) and 11.75 in. long at an add-on level=7.7mg/m² (12 g/m², 1.19 mg/cm²). The distance between the stripes is 0.31in.

The article to which skin care composition is added in this example iscommercially available Pampers Premium (Size 4) diapers, available fromProcter & Gamble, Cincinnati, Ohio.

Example 2 Method of Improving Skin Health

An infant weighing 20 lbs who typically exhibits moderate diaper rashand erythema is diapered for a period of 21 days using the diaper ofExample 1. The infant's diaper is changed according to the routinepatterns of the caregiver. (Typical diapering patterns consist ofchanges every three to four hours during the day and application of afresh diaper before overnight sleep.) No intervention by the caregiver,in the form of manual application of skin protective or moisturerepellent products, occurs during this period. During the 21 day period,the subject is observed to have reduced severity of rash and erythema.

Example 3 Method of Improving Skin Health

An active incontinent adult weighing 165 lbs. who constantly usesabsorbent articles and who persistently has mild erythema uses an adultincontinent product analogous to the diaper of Example 1 for a period ofat least about 5 days. The subject's article is changed according to theroutine patterns of the user. (Typical changing patterns consist ofchanges every four to five hours during the day and application of afresh article before overnight sleep.) No intervention by the user, inthe form of manual application of skin protective or moisture repellentproducts, occurs during this period. At the end of the 5 day period, thesubject is observed to have reduced or resolved erythema.

Example 4 Method of Improving Skin Health

An infant weighing 32 lbs. exhibiting mild diaper rash and erythema isdiapered for a period of at least about 5 days using the diaper ofExample 1 during overnight sleep only. (That is, a untreated article isused throughout the day.) The infant's diaper is changed according tothe routine patterns of the caregiver. No intervention by the caregiver,in the form of manual application of skin protective or moisturerepellent products, occurs during this period. At the end of the 5 dayperiod, the subject is observed to have reduced or resolved rash anderythema.

Example 5 Method of Maintaining Skin Health

An infant weighing 25 lbs. exhibiting no diaper rash or erythema isdiagnosed with otitis media and is prescribed a course of systemicantibiotics. Based on experience with conventional (untreated) diapers,the caregiver expects that the infant will develop erythema and/ordiaper rash resulting from loose stools. As a result, diapers such asthat described in Example 1 are used continuously throughout the periodof administration of the antiobotic. No intervention by the caregiver,in the form of manual application of skin protective or moisturerepellent products, occurs during this period. Throughout the period ofantibiotic administration, the subject exhibits no erythema or diaperrash.

Example 6 Breathable Films

Three breathable films with varying polymer blends were prepared andthen each of the films were prepared. Each of the film formulationscontained, on a total weight percent basis, 65% English China Supercoatcalcium carbonate (CaCO₃) with a 1 micron average particle size and a 7micron top cut. The calcium carbonate was obtained form ECCA CalciumProducts, Inc. in Sylacauga, Ala., a division of ECC International. Thecalcium carbonate was blended with 15-25% by weight of linear lowdensity polyethylene made from a blend of DOWLEX® 2517 linear lowdensity polyethylene and DOWLEX® 2532 linear low density polyethyleneblended in a weight ratio of 1:4 such that the melt indenx of the blendwas 10 M.I. (/10 minutes at 190° F.). The DOWLEX® polymers are availablefrom Dow Chemical U.S.A., Midland, Mich. The remaining 10-20% by weightof the formulation comprised Himont KS051P polypropylene-based polymerfrom Himont, USA of Wilmington, Del. The KS051P polymer is an olefinicthermoplastic elastomer or TPO multistep reactor product wherein anamorphous ethylene propylene random copolymer is molecularly dispersedin a predominately semicrystalline high polypropylene monmer/lowethylene monomer continuous matrix. The amorphous component acts as thetacktifying or bonding agent as it begins to soften at about 55° C. Asshown in Table I below, sample 1 contained 65% calcium carbonate, 10%KS051P polymer and 25% linear low density polyethylene. Sample 2contained 65% calcium carbonate, 15% KS051P polymer and 20% linear lowdensity polyethylene. The third sample contained 65% calcium carbonate,20% KS051P polymer and 15% linear low density polyethylene. Each of thethree formulations were blown into films at a melt temperature of 375°F. (191° C.) at a blow up ratio of approximately 1.7 to produce filmshaving an unstretched gauge of approximately 1.25 mils (50 gsm). Each ofthe films was subsequently stretched on a machine direction orientation(MDO) unit at a stretch ratio of 3× and at a temperature of 140° F. (60°C.). The resultant films were breathable as indicated by the water vaportransmission rate data set forth in Table II below and has basis weightsof approximately 14 grams per square meter.

TABLE II CaCO3 LLDPE KS051P WVTR (% by (% by (% by (g/m²/ SAMPLE weight)weight) weight) 24 hr) 1 65 25 10 4530 2 65 20 15 4300 3 65 15 20 3710

Example 7 Breathable Films

In this Example, 65% by weight calcium carbonate and 30% by weightlinear low density polyethylene were blended. As shown by Table III, tothe basic blend there was added a series of recognized tacktifying orbonding agents in a weight percent of 5%. The bonding agents includedREGALREZ® 1094, 3102 and 1126 bonding agents as well as ZONATAC® 501Land EASTMAN® 1023PL bonding agents. In addition, the film formulationfrom sample 2 of Example 6 was also formed into a film in the samefashion as described with respect to Example 6. Each of the films wasblown at a blow-up ratio of 1.7 to a guage of approximately 1.5 mils (60gsm). The films were stretched at 146° F. (63° C.) in the machinedirection to three times (3×) their original length. This stretchingtemperature which was below the melting point (235° F./113° C.) of thepredominately linear polyolefin polymers. The water vapor transmissionrate for each of the films was measured. The results are presented inTable III below.

TABLE III WVTR CaCO3 LLDPE (g/m²/ Bonding Agent Wt % Wt % Wt % 24 hr)KS050 1 65 20 4300 REGALREZ ® 1094 5 65 30 2300 REGALREZ ® 3102 5 65 303840 REGALREZ ® 1126 5 65 30 3198 ZONATAC ® 501L 5 65 30 2990 EASTMAN ®1023PL 5 65 30 4900

What is claimed is:
 1. A disposable absorbent article which defines afront waist region, a rear waist region, and a crotch region whichinterconnects said front and rear waist regions, said absorbent articlecomprising: a) a vapor permeable backsheet; b) a liquid pervioustopsheet which is positioned in facing relation with said backsheet; c)an absorbent core located between said backsheet and said topsheet, saidabsorbent core including a dual core system; and d) a skin carecomposition, wherein said skin care composition is applied nonuniformlyto a wearer-contacting surface of the disposable absorbent article suchthat a percent open area in the crotch region is between 25% and 75%. 2.The disposable absorbent article of claim 1, wherein the percent openarea in the crotch region is between 30% and 70%.
 3. The disposableabsorbent article of claim 1, wherein the percent open area in thecrotch region is between 35% and 65%.
 4. The disposable absorbentarticle of claim 1, wherein the skin care composition is applied to thetopsheet.
 5. The disposable absorbent article of claim 4, wherein theskin care composition is applied in alternating longitudinal stripes ofrelatively higher and relatively lower amounts of the skin carecomposition.
 6. The disposable absorbent article of claim 5, whereineach stripe has a width between 0.1 inch and 0.75 inch.
 7. Thedisposable absorbent article of claim 5, wherein the stripes ofrelatively lower amounts of skin care composition are untreated.
 8. Thedisposable absorbent article of claim 4, wherein the skin carecomposition is applied in a non-uniform pattern to at least one otherarticle component selected from the group consisting of one or morecuffs, a waistband, and a side panel.
 9. The disposable absorbentarticle of claim 4, wherein the topsheet is untreated in the crotchregion.
 10. The disposable absorbent article of claim 4, wherein theskin care composition is applied in a pattern of droplets, discretedots, stripes, or spirals.
 11. The disposable absorbent article of claim4, wherein the skin care composition is applied in an amount rangingfrom 0.05 mg/m² to 35 mg/m².
 12. The disposable absorbent article ofclaim 11, wherein the skin care composition is applied in an amountranging from 1 mg/m² to 25 mg/m².
 13. The disposable absorbent articleof claim 12, wherein the skin care composition is applied in an amountranging from 4 mg/m² to 20 mg/m².
 14. A disposable absorbent articlewhich defines a front waist region, a rear waist region, and a crotchregion which interconnects said front and rear waist regions, saidabsorbent article comprising: a) a vapor permeable backsheet; b) aliquid pervious topsheet which is positioned in facing relation withsaid backsheet; c) an absorbent core located between said backsheet andsaid topsheet, said absorbent core including a dual core system; and d)a skin care composition, wherein said skin care composition is appliedto a non-wearer contacting surface of the disposable absorbent article.15. The disposable absorbent article of claim 14, wherein the skin carecomposition is applied to one or more materials positioned beneath thewearer contacting surface.
 16. The disposable absorbent article of claim14, wherein the skin care composition is applied nonuniformly.
 17. Thedisposable absorbent article of claim 16, wherein the skin carecomposition is applied such that a percent open area is between 25% and75%.
 18. The disposable absorbent article of claim 16, wherein the skincare composition is applied such that a percent open area is between 30%and 70%.
 19. The disposable absorbent article of claim 16, wherein theskin care composition is applied such that a percent open area isbetween 35% and 65%.
 20. The disposable absorbent article of claim 16,wherein the skin care composition is applied in a pattern of droplets,discrete dots, stripes, or spirals.